
        <html>
        <head>
            <style>
                body { font-family: Arial, sans-serif; line-height: 1.6; margin: 20px; }
                h3 { color: #333; }
                .question { margin-bottom: 15px; }
                .options { margin-left: 20px; margin-bottom: 10px; }
                .solution { background: #f8f9fa; padding: 10px; border-left: 4px solid #007bff; }
                .credits { text-align: center; margin-top: 20px; font-size: 18px; }
                .rainbow-text { 
                    background: linear-gradient(90deg, red, orange, yellow, green, blue, indigo, violet); 
                    -webkit-background-clip: text; 
                    color: transparent; 
                    font-weight: bold; 
                }
            </style>
        </head>
        <body>
        
            <div class="question">
                <h3>Question No: 1</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A 55-year-old male patient presents with hypertension. He has a history of diabetes mellitus and chronic kidney disease (CKD). Which of the following is the most appropriate first-line antihypertensive therapy for this patient?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Calcium channel blockers (CCBs)</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>ACE inhibitors (ACE-Is)</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Beta blockers</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Thiazide diuretics</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>ACE inhibitors</strong> are the <strong>drug of choice (DOC)</strong> in hypertensive patients with <strong>diabetes mellitus and CKD</strong> due to their ability to:</li>
<ul>
<li><strong>Reduce intraglomerular pressure</strong>: ACE-Is dilate the <strong>efferent arterioles</strong>, thereby decreasing glomerular hypertension and protecting against <strong>progression of diabetic nephropathy</strong>.</li>
<li><strong>Reduce albuminuria</strong>: They significantly lower <strong>proteinuria</strong>, which is a key marker for CKD progression.</li>
<li><strong>Cardiovascular benefits</strong>: ACE-Is reduce the risk of major cardiovascular events, which is vital in diabetic and CKD populations at high cardiovascular risk.</li>
<li><strong>Glycemic neutrality</strong>: Unlike some other antihypertensives, &lsquo;ACE-Is&rsquo; do not worsen glycemic control, making them safer for diabetic patients.</li>
</ul>
</ul>
<p><strong>Distractors:</strong></p>
<p><strong>Calcium channel blockers (CCBs):</strong></p>
<ul>
<li>While CCBs effectively lower blood pressure, they do not provide the <strong>renal protective benefits</strong> of ACE-Is or ARBs.</li>
<li>CCBs are preferred in <strong>isolated systolic hypertension</strong> or when ACE-Is are not tolerated, but they are not the first-line choice in CKD with diabetes.</li>
</ul>
<p><strong>Beta blockers:</strong></p>
<ul>
<li>Beta blockers are <strong>not first-line agents</strong> for hypertension with diabetes or CKD.</li>
<li>They can <strong>mask hypoglycemia</strong> in diabetes and do not have significant effects on reducing proteinuria or preserving renal function.</li>
<li>Reserved for specific indications like <strong>ischemic heart disease</strong> or <strong>heart failure</strong> in these patients.</li>
</ul>
<p><strong>Thiazide diuretics:</strong></p>
<ul>
<li>Thiazides are effective in controlling blood pressure but may exacerbate <strong>hyperglycemia</strong> and <strong>hyperlipidemia</strong> in diabetic patients.</li>
<li>They lack the <strong>renoprotective and proteinuria-reducing effects</strong> of &lsquo;ACE-Is&rsquo;, making them less favorable in CKD.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 2</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A 45-year-old male with a history of hypertension was prescribed clonidine for blood pressure control. He decides to abruptly stop taking the medication. Which of the following adverse effects is most likely to occur?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Rebound hypertension</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Orthostatic hypotension</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Bradycardia</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hyperkalemia</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Clonidine withdrawal hypertension</strong> is a classic example of <strong>Type E (End of Use) ADR</strong>.</li>
<li>Clonidine is a <strong>centrally acting alpha-2 agonist</strong> that suppresses sympathetic outflow from the CNS, leading to reduced blood pressure. Abrupt cessation causes a <strong>rebound surge of sympathetic activity</strong>, resulting in <strong>rebound hypertension</strong>.</li>
<li>The severity of rebound hypertension depends on the dose and duration of clonidine use. Tapering the medication gradually prevents this complication.</li>
</ul>
<p><strong>Distractors:</strong></p>
<ul>
<li><strong>Orthostatic hypotension:</strong> Orthostatic hypotension is not associated with clonidine withdrawal but may occur as a side effect during clonidine use due to its blood pressure-lowering properties.</li>
</ul>
<ul>
<li><strong>Bradycardia:</strong> Bradycardia is an expected effect of clonidine due to its ability to reduce sympathetic tone, but it does not occur during withdrawal. Instead, withdrawal leads to tachycardia due to increased sympathetic activity.</li>
<li><strong>Hyperkalemia:</strong> Hyperkalemia is not a known adverse effect of clonidine withdrawal. It may be associated with other drugs like ACE inhibitors, potassium-sparing diuretics, or aldosterone antagonists.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 3</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A 50-year-old male with a history of alcoholic liver disease presents with abdominal distension and lower limb swelling. On examination, he has tense ascites and bilateral pedal edema. Blood tests reveal low serum albumin, elevated liver enzymes, and hyperaldosteronism. Despite being on furosemide therapy, his symptoms persist. Which of the following is the most appropriate addition to his treatment plan?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hydrochlorothiazide</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Spironolactone</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Mannitol</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Eplerenone</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Spironolactone</strong>: <strong>Cirrhotic edema</strong> and ascites in liver disease are driven by <strong>secondary hyperaldosteronism</strong>, which leads to sodium retention and potassium excretion.</li>
<li><strong>Spironolactone</strong>, a <strong>non-selective aldosterone antagonist</strong>, directly inhibits aldosterone activity, reducing sodium and water retention while conserving potassium.</li>
<li>It is particularly effective for patients with liver disease, as it addresses the <strong>pathophysiological cause</strong> of fluid accumulation rather than just symptom control.</li>
<li>Studies demonstrate that spironolactone is the <strong>first-line therapy</strong> for managing <strong>ascites and peripheral edema</strong> in cirrhotic patients.</li>
</ul>
<p><strong>Distractors:</strong></p>
<p><strong>Hydrochlorothiazide:</strong></p>
<ul>
<li><strong>Thiazide diuretic</strong> that acts on the <strong>distal convoluted tubule</strong> to promote sodium and water excretion.</li>
<li>Effective for <strong>hypertension</strong> and <strong>mild edema</strong>, but it does not target the <strong>hyperaldosteronism</strong> seen in cirrhotic patients.</li>
<li>Can cause <strong>hypokalemia</strong>, which is especially undesirable in patients with liver disease.</li>
</ul>
<p><strong>Mannitol:</strong></p>
<ul>
<li><strong>Osmotic diuretic</strong> used for conditions such as <strong>increased intracranial pressure</strong> or <strong>acute glaucoma</strong>.</li>
<li>It increases plasma osmolality, pulling water out of tissues into the bloodstream, but it does not address <strong>sodium retention</strong> or <strong>aldosterone-mediated</strong> fluid retention.</li>
<li>Not suitable for treating ascites or peripheral edema in cirrhosis.</li>
</ul>
<p><strong>Eplerenone:</strong></p>
<ul>
<li>A <strong>selective aldosterone antagonist</strong> that avoids the anti-androgenic and progestogenic side effects of spironolactone.</li>
<li>Primarily indicated for <strong>hypertension</strong> and <strong>heart failure with reduced ejection fraction (HFrEF)</strong>, not as effective in severe ascites due to cirrhosis.</li>
<li>It is <strong>costlier</strong> and less commonly used for cirrhotic edema compared to spironolactone.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 4</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following best describes the pharmacological action of buprenorphine?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Full agonist at mu and partial agonist at kappa receptors</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Partial agonist at mu and antagonist at kappa receptors</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Antagonist at both mu and kappa receptors</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Full agonist at both mu and kappa receptors</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Mu-Opioid Receptor (MOR) as a Partial Agonist:</strong></p>
<ul>
<li><strong>Buprenorphine</strong> is a <strong>partial agonist</strong> at the <strong>mu-opioid receptor</strong>. This means it <strong>activates</strong> the receptor to produce analgesic effects (pain relief), but its effect is <strong>limited</strong> compared to <strong>full agonists</strong> like <strong>morphine</strong> or <strong>fentanyl</strong>.</li>
<li>This <strong>ceiling effect</strong> at the mu receptor means that <strong>buprenorphine</strong> does not cause the same level of <strong>respiratory depression</strong>, <strong>euphoria</strong>, or <strong>sedation</strong> seen with full agonists, making it <strong>safer</strong> for long-term use, particularly in the treatment of <strong>opioid use disorder</strong> (OUD).</li>
<li>This <strong>partial activation</strong> provides effective <strong>pain relief</strong> with <strong>less risk of addiction</strong> and <strong>overdose</strong> compared to other opioids.</li>
</ul>
<p><strong>Kappa-Opioid Receptor (KOR) Antagonism: &nbsp;</strong></p>
<ul>
<li>Buprenorphine acts as an <strong>antagonist</strong> at the <strong>kappa-opioid receptor</strong>. The <strong>kappa receptors</strong> are associated with <strong>dysphoric effects</strong>, <strong>psychotomimetic effects</strong> (hallucinations, confusion), and <strong>depression</strong>.</li>
<li>By blocking these receptors, buprenorphine <strong>reduces the potential for negative side effects</strong> like <strong>dysphoria</strong> and <strong>hallucinations</strong>, which are commonly seen with drugs that act on kappa receptors (such as <strong>salvinorin A</strong> or <strong>nalbuphine</strong>).</li>
<li>This receptor profile enhances <strong>buprenorphine's tolerability</strong> in patients, especially in <strong>opioid dependence treatment</strong>, where <strong>stabilization</strong> without euphoria or intense cravings is a key goal.</li>
</ul>
<p><strong>Distractors:</strong></p>
<ul>
<li><strong>Full agonist at mu and partial agonist at kappa receptors: </strong>Incorrect: Buprenorphine is not a full agonist at the mu receptor. It is a partial agonist at mu receptors, meaning it has a limited effect on mu receptor activation, providing a ceiling effect and lower risk of respiratory depression. It also blocks kappa receptors, not activating them.</li>
</ul>
<ul>
<li><strong>Antagonist at both mu and kappa receptors: Incorrect</strong>: Buprenorphine is <strong>not an antagonist</strong> at the <strong>mu receptor</strong>. Instead, it <strong>partially activates</strong> the mu receptor, which is key to its analgesic action. It <strong>blocks</strong> the kappa receptor, but it does not block mu.</li>
<li><strong>Full agonist at both mu and kappa receptors: Incorrect</strong>: Buprenorphine is <strong>not a full agonist</strong> at either the <strong>mu</strong> or <strong>kappa</strong> It has <strong>partial agonist</strong> activity at mu receptors and <strong>antagonist</strong> activity at kappa receptors, which differentiates it from drugs that activate both receptors fully (like morphine).</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 5</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A 58-year-old male patient with a history of chronic stable angina is admitted to the hospital with increasing chest pain despite taking his usual nitroglycerin tablets. The cardiologist decides to start the patient on a new medication to improve his symptoms and reduce the frequency of angina attacks. The doctor prescribes Nicorandil. Which of the following best explains the mechanism of action of Nicorandil in relieving the patient&rsquo;s angina?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Nicorandil inhibits the sodium-potassium ATPase pump in the myocardial cells, reducing myocardial contractility.</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Nicorandil activates the ATP-sensitive potassium channels, leading to coronary vasodilation and reduced myocardial oxygen demand.</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Nicorandil stimulates the beta-adrenergic receptors in the heart, increasing heart rate and improving myocardial oxygen supply.</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Nicorandil increases the release of nitric oxide from endothelial cells, causing systemic vasoconstriction.</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Nicorandil activates the ATP-sensitive potassium channels, leading to coronary vasodilation and reduced myocardial oxygen demand: Nicorandil</strong> is a <strong>potassium channel opener</strong> that works by activating ATP-sensitive potassium (K_ATP) channels in vascular smooth muscle. This leads to <strong>vasodilation</strong>, particularly in the <strong>coronary arteries</strong>, which increases blood flow to the heart muscle. This effect helps reduce the <strong>myocardial oxygen demand</strong> and improves oxygen delivery to the heart, which is essential for managing <strong>chronic stable angina</strong>. By reducing the workload of the heart and increasing coronary blood flow, Nicorandil helps prevent angina attacks.</li>
<li><strong>Nicorandil inhibits the sodium-potassium ATPase pump in the myocardial cells, reducing myocardial contractility: </strong>This description refers to the mechanism of <strong>digoxin</strong>, not Nicorandil. Digoxin inhibits the <strong>Na+/K+ ATPase pump</strong>, leading to increased intracellular calcium levels and enhanced myocardial contractility, but this is not how Nicorandil works. Nicorandil&rsquo;s action is primarily related to potassium channel opening and vasodilation, not directly influencing myocardial contractility.</li>
<li><strong>Nicorandil stimulates the beta-adrenergic receptors in the heart, increasing heart rate and improving myocardial oxygen supply: </strong>This is the mechanism of action of <strong>beta-agonists</strong> like <strong>isoproterenol</strong> or <strong>dobutamine</strong>, which stimulate beta-adrenergic receptors and increase heart rate and contractility. Nicorandil, however, does not act on adrenergic receptors but on potassium channels to induce vasodilation and reduce myocardial oxygen demand.</li>
<li><strong>Nicorandil increases the release of nitric oxide from endothelial cells, causing systemic vasoconstriction: </strong>This is incorrect because while <strong>nitric oxide</strong> plays a role in the vasodilation effects of some drugs (e.g., nitrates), <strong>Nicorandil</strong> does not induce vasoconstriction. Instead, it induces <strong>vasodilation</strong> via potassium channel opening and also has nitrate-like effects. The statement about <strong>systemic vasoconstriction</strong> is contrary to the mechanism of Nicorandil.&nbsp;&nbsp;</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 6</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A 72-year-old female patient with a history of acute deep vein thrombosis (DVT) is being considered for anticoagulation therapy. The physician is looking for an anticoagulant that inhibits only Factor Xa, and the patient requires subcutaneous administration for both prophylaxis and treatment. After evaluating the patient&rsquo;s medical history and the desired drug properties, the physician prescribes an anticoagulant. Which of the following anticoagulants inhibits only Factor Xa and is most appropriate for this patient?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Unfractionated Heparin (UFH)</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Low Molecular Weight Heparin (LMWH)</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Fondaparinux</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Warfarin</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Fondaparinux:</strong></li>
</ul>
<ul>
<ul>
<li><strong>Fondaparinux</strong> is a <strong>selective Factor Xa inhibitor</strong> that works by binding to <strong>antithrombin III</strong>, which then specifically inhibits <strong>Factor Xa</strong>. It does not inhibit <strong>Factor IIa (thrombin)</strong>, making it distinct from <strong>unfractionated heparin (UFH)</strong> and <strong>LMWH</strong>.</li>
<li>Fondaparinux is administered <strong>subcutaneously</strong> and is used for both <strong>prophylaxis and treatment</strong> of thromboembolic events like <strong>DVT</strong>, <strong>pulmonary embolism (PE)</strong>, and in <strong>hip and knee surgeries</strong>.</li>
<li>Fondaparinux has a <strong>longer half-life</strong> and does not require routine monitoring (like UFH), making it more convenient for outpatient use or for patients who are not easily accessible for frequent lab testing.</li>
</ul>
</ul>
<ul>
<li><strong>Unfractionated Heparin (UFH):</strong></li>
</ul>
<ul>
<ul>
<li><strong>UFH</strong> is a <strong>non-selective anticoagulant</strong> that inhibits both <strong>Factor Xa and Factor IIa (thrombin)</strong>. It requires <strong>frequent monitoring</strong> via aPTT (activated partial thromboplastin time) and is typically administered <strong>intravenously</strong> for treatment or <strong>subcutaneously</strong> for prophylaxis. Therefore, it does not fit the criteria of <strong>selectively inhibiting only Factor Xa</strong>.</li>
</ul>
</ul>
<ul>
<li><strong>Low Molecular Weight Heparin (LMWH):</strong></li>
</ul>
<ul>
<ul>
<li><strong>LMWH</strong> inhibits both <strong>Factor Xa</strong> and to a lesser extent <strong>Factor IIa</strong>. It is more selective for <strong>Factor Xa</strong> than UFH, but it still affects <strong>Factor IIa</strong>, making it less specific than Fondaparinux. It is commonly used for <strong>DVT prophylaxis and treatment</strong>, but it does not exclusively inhibit <strong>Factor Xa</strong>.</li>
</ul>
</ul>
<ul>
<li><strong>Warfarin:</strong></li>
</ul>
<ul>
<ul>
<li><strong>Warfarin</strong> is a <strong>vitamin K antagonist</strong> that inhibits the synthesis of clotting factors <strong>II, VII, IX, and X</strong>, but it does not directly inhibit <strong>Factor Xa</strong>. It works through a completely different mechanism than Fondaparinux and is typically used for <strong>long-term anticoagulation</strong> and not for <strong>acute treatment</strong> like Fondaparinux. Additionally, <strong>warfarin</strong> requires monitoring of <strong>INR (International Normalized Ratio)</strong>. &nbsp;&nbsp;&nbsp;</li>
</ul>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 7</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A 35-year-old woman with Type 2 diabetes, PCOS, and metabolic syndrome is prescribed a medication that lowers hepatic gluconeogenesis by stimulating AMPK. Which of the following is the most appropriate medication?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Glibenclamide</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Metformin</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Insulin</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Acarbose</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Metformin</strong> is a <strong>biguanide</strong> and the <strong>first-line treatment</strong> for <strong>Type 2 diabetes mellitus (T2DM)</strong>, <strong>polycystic ovary syndrome (PCOS)</strong>, and <strong>metabolic syndrome</strong>.</li>
</ul>
<ul>
<ul>
<li>It works by <strong>stimulating AMP-activated protein kinase (AMPK)</strong>, which <strong>inhibits hepatic gluconeogenesis</strong> (the liver's production of glucose), thus reducing <strong>blood glucose levels</strong>. Additionally, <strong>Metformin</strong> enhances insulin sensitivity and reduces intestinal glucose absorption.</li>
</ul>
</ul>
<ul>
<li><strong>Glibenclamide (Sulfonylurea):</strong></li>
</ul>
<ul>
<ul>
<li><strong>Glibenclamide</strong> works by stimulating insulin release from pancreatic beta cells, but it does not affect <strong>hepatic gluconeogenesis</strong> or <strong>AMPK</strong>. It is typically used in <strong>Type 2 diabetes</strong>, but it is not the preferred drug for patients with <strong>PCOS</strong> or <strong>metabolic syndrome</strong> due to risk of <strong>hypoglycemia</strong> and lack of <strong>insulin sensitivity</strong> improvement.</li>
</ul>
</ul>
<ul>
<li><strong>Insulin: </strong></li>
</ul>
<ul>
<ul>
<li><strong>Insulin</strong> is primarily used in <strong>Type 1 diabetes</strong> and in <strong>advanced Type 2 diabetes</strong> when oral agents are ineffective. <strong>Insulin</strong> does not act on <strong>AMPK</strong> or <strong>hepatic gluconeogenesis</strong> and is typically reserved for later stages of <strong>diabetes</strong> or for patients with <strong>insulin deficiency</strong>.</li>
</ul>
</ul>
<ul>
<li><strong>Acarbose:</strong></li>
</ul>
<ul>
<ul>
<li><strong>Acarbose</strong> inhibits <strong>alpha-glucosidase</strong>, reducing the breakdown of carbohydrates in the intestine, which decreases post-meal glucose spikes. However, it does not affect <strong>hepatic gluconeogenesis</strong> or <strong>AMPK</strong>, making it less effective as a primary agent in managing <strong>PCOS</strong> or <strong>metabolic syndrome</strong>.</li>
</ul>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 8</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A 7-year-old boy with Lennox-Gastaut Syndrome (LGS) is experiencing multiple types of seizures, including tonic, atonic, and atypical absence seizures. His doctor decides to initiate treatment with the drug of choice (DOC) for managing LGS. Which of the following is the most appropriate first-line medication for this condition?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Topiramate</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Valproate</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Lamotrigine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Rufinamide</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Valproate</strong> is the <strong>drug of choice (DOC)</strong> for <strong>Lennox-Gastaut syndrome (LGS)</strong>. It is effective in controlling the <strong>multiple seizure types</strong> commonly seen in LGS, including <strong>tonic</strong>, <strong>atonic</strong>, and <strong>absence seizures</strong>. Valproate works by increasing <strong>GABAergic activity</strong>, stabilizing neuronal membranes, and inhibiting sodium channels, thus reducing seizure frequency.</li>
<li><strong>Topiramate: Topiramate</strong> is <strong>used as an adjunct therapy</strong> in <strong>LGS</strong> but is not considered the first-line treatment. It is effective for partial and generalized seizures but has a more limited role in managing the diverse seizure types seen in LGS compared to <strong>Valproate</strong>.</li>
<li><strong>Lamotrigine: Lamotrigine</strong> is used for the treatment of <strong>partial seizures</strong> and <strong>generalized tonic-clonic seizures</strong>, but it is not the first-line drug for <strong>LGS</strong>, which often requires a broader spectrum of action.</li>
<li><strong>Rufinamide: Rufinamide</strong> is another option for treating <strong>LGS</strong>, specifically for its <strong>atypical absence</strong> and <strong>tonic</strong> It is often used <strong>in combination</strong> with other agents rather than as a first-line drug. &nbsp;&nbsp;&nbsp;</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 9</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A 60-year-old patient with atrial fibrillation is being prescribed antiarrhythmic therapy. The physician is concerned about the potential for QT prolongation. Which of the following Class 1a antiarrhythmic drugs can cause QT prolongation? (Select all that apply)</strong></p>
<p style="line-height: 115%;">A) <strong>Quinidine</strong><br />B) <strong>Procainamide</strong><br />C) <strong>Disopyramide</strong><br />D) <strong>Lidocaine</strong><br />E) <strong>Flecainide <o:p></o:p></strong></p>
<p style="line-height: 115%;"><strong>Choose from the options below:<o:p></o:p></strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>A, B and C</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>A and C</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>D only</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>A and D</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Class 1a antiarrhythmics</strong> (e.g., <strong>Quinidine</strong>, <strong>Procainamide</strong>, and <strong>Disopyramide</strong>) are known to cause <strong>QT prolongation</strong> as a side effect. These drugs work by blocking <strong>sodium channels</strong> and also have <strong>potassium channel blocking</strong> effects, which can delay repolarization and increase the duration of the <strong>QT interval</strong> on an ECG. This can lead to an increased risk of <strong>Torsades de Pointes</strong>, a potentially life-threatening arrhythmia.</li>
</ul>
<ul>
<ul>
<li><strong>Quinidine</strong> (A) inhibits <strong>sodium</strong> and <strong>potassium</strong> channels, which leads to <strong>QT prolongation</strong> and increases the risk of arrhythmias.</li>
<li><strong>Procainamide</strong> (B) also blocks <strong>sodium</strong> and <strong>potassium</strong> channels and is associated with <strong>QT prolongation</strong>, particularly at higher doses or in patients with renal dysfunction.</li>
<li><strong>Disopyramide</strong> (C) is similar to Quinidine and Procainamide in terms of its <strong>QT prolonging</strong> effects.</li>
</ul>
</ul>
<ul>
<li><strong>Lidocaine</strong>: <strong>Lidocaine</strong> is a <strong>Class 1b</strong> antiarrhythmic and works primarily by <strong>sodium channel blockade</strong>. It does <strong>not</strong> cause <strong>QT prolongation</strong> and is typically used in emergency situations for ventricular arrhythmias, such as <strong>ventricular tachycardia</strong>.</li>
<li><strong>Flecainide</strong>: <strong>Flecainide</strong> is a <strong>Class 1c</strong> It does not significantly cause <strong>QT prolongation</strong> but can be associated with <strong>proarrhythmic effects</strong> in patients with structural heart disease.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 10</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A 65-year-old male with congestive heart failure presents with symptoms of nausea, yellow vision, and palpitations. ECG shows an arrhythmia. Which of the following is the most characteristic arrhythmia caused by digoxin toxicity?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Ventricular bigeminy</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Atrial tachycardia with AV block</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Atrial fibrillation</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Ventricular tachycardia</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Digoxin inhibits the Na⁺/K⁺-ATPase pump, leading to an increase in intracellular Na⁺, which promotes Ca&sup2;⁺ influx via the Na⁺/Ca&sup2;⁺ exchanger. This enhances myocardial contractility (<strong>positive inotropy</strong>) and slows conduction through the AV node (<strong>negative chronotropy</strong>). However, toxicity occurs with excessive levels, resulting in:</li>
<li><strong>Increased automaticity</strong>: Due to calcium overload, ectopic foci in the atria become hyperactive.</li>
<li><strong>Decreased AV node conduction</strong>: Digoxin promotes vagal activity, leading to AV block.</li>
<li><strong>Combination of effects</strong>: This unique interplay causes <strong>atrial tachycardia with AV block</strong>, the <strong>most characteristic arrhythmia</strong> of digoxin toxicity. The atrial tachycardia arises from ectopic atrial foci, while AV block results from suppressed conduction through the AV node.</li>
</ul>
<p><strong>Distractors:</strong></p>
<ul>
<li><strong>Ventricular bigeminy: Most common arrhythmia</strong> seen in digoxin toxicity but not the most characteristic. Bigeminy arises due to enhanced ectopic ventricular foci, reflecting increased automaticity. It lacks the hallmark combination of atrial tachycardia with AV block seen in digoxin toxicity.</li>
<li><strong>Atrial fibrillation:</strong> Digoxin is used to <strong>manage</strong> atrial fibrillation due to its ability to slow AV node conduction, controlling ventricular response. While digoxin toxicity may exacerbate ectopic atrial activity, it more commonly causes <strong>atrial tachycardia with AV block</strong>, not atrial fibrillation.</li>
<li><strong>Ventricular tachycardia:</strong> This is rare in digoxin toxicity and generally occurs in severe cases, especially with coexisting risk factors such as hypokalemia. While digoxin-induced ventricular arrhythmias are dangerous, <strong>atrial tachycardia with AV block</strong> is more characteristic.</li>
</ul>
<p><strong>Important Clinical Points from the Content: &nbsp;</strong></p>
<p><strong>Side Effects of Digoxin Toxicity:</strong></p>
<ol>
<li><strong>Most common and earliest signs:</strong></li>
<ul>
<li><strong>Nausea and vomiting</strong> due to stimulation of the chemoreceptor trigger zone.</li>
</ul>
<li><strong>Specific symptom:</strong></li>
<ul>
<li><strong>Xanthopsia (yellow vision)</strong> caused by effects on the retina.</li>
</ul>
<li><strong>Gynecomastia: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></li>
<ul>
<li>Rarely occurs due to digoxin&rsquo;s estrogenic effects.</li>
</ul>
</ol>
<p><strong>Arrhythmias in Digoxin Toxicity:</strong></p>
<ol>
<li><strong>Most common:</strong> Ventricular bigeminy.</li>
<li><strong>Most characteristic:</strong> Atrial tachycardia with AV block.</li>
</ol>
<p><strong>Risk Factors for Digoxin Toxicity:</strong></p>
<p>(Mnemonic: <strong>KMC in Manipal Rocks</strong>)</p>
<ul>
<li><strong>K:</strong> <strong>Hypokalemia</strong> - Reduced K⁺ enhances digoxin binding to Na⁺/K⁺ ATPase, increasing its toxic effects.</li>
<li><strong>M:</strong> <strong>Hypomagnesemia</strong> - Low Mg&sup2;⁺ exacerbates arrhythmias by altering myocardial electrical activity.</li>
<li><strong>C in:</strong> <strong>Hypercalcemia</strong> - Increased Ca&sup2;⁺ amplifies digoxin-induced calcium overload.</li>
<li><strong>Manipal:</strong> <strong>Myocardial infarction (MI)</strong> - Ischemic myocardium is more prone to digoxin-induced arrhythmias.</li>
<li><strong>Rocks:</strong> <strong>Renal failure</strong> - Impaired excretion of digoxin raises plasma levels, increasing toxicity risk.</li>
</ul>
<p><strong>Contraindications:</strong></p>
<ul>
<li><strong>WPW Syndrome (Wolff-Parkinson-White):</strong>
<ul>
<li>Digoxin enhances conduction through the accessory pathway, worsening tachyarrhythmias.</li>
</ul>
</li>
<li><strong>HOCM (Hypertrophic Obstructive Cardiomyopathy):</strong>
<ul>
<li>Positive inotropic effects can exacerbate obstruction in HOCM, worsening symptoms.</li>
</ul>
</li>
</ul>
<p><strong>Management of Digoxin Toxicity:</strong></p>
<ul>
<li><strong>Antidote: Digibind</strong> (digoxin-specific antibody fragments) binds free digoxin, neutralizing its effects.</li>
<li><strong>Supportive care:</strong> Correct <strong>hypokalemia</strong> and <strong>hypomagnesemia</strong> to reduce arrhythmogenic risk.</li>
<li><strong>Arrhythmias:</strong> Manage severe arrhythmias with antiarrhythmic drugs (e.g., lidocaine) as indicated.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 11</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A 45-year-old patient undergoing chemotherapy for lung cancer develops severe nausea and vomiting after cisplatin administration. He is also at risk of nephrotoxicity due to the treatment. Which of the following drugs is used to mitigate cisplatin-induced nephrotoxicity?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Ondansetron</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Mannitol</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Amifostine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Furosemide</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Amifostine is a <strong>radioprotective and cytoprotective agent</strong> that prevents cisplatin-induced nephrotoxicity. It acts as a prodrug, metabolized by alkaline phosphatase in normal tissues to its active form. This active metabolite scavenges free radicals and binds to toxic cisplatin metabolites in the renal tubules, reducing kidney damage.</li>
</ul>
<p><strong>Distractors:</strong></p>
<ul>
<li><strong>Ondansetron:</strong></li>
<ul>
<li><strong>Use:</strong> Highly effective in managing chemotherapy-induced nausea and vomiting by blocking <strong>5-HT3 (serotonin) receptors</strong> in the chemoreceptor trigger zone (CTZ).</li>
<li><strong>Limitation:</strong> Does not protect against nephrotoxicity.</li>
</ul>
<li><strong>Mannitol:</strong></li>
<ul>
<li><strong>Use:</strong> Osmotic diuretic used to promote diuresis, helping to flush toxic cisplatin metabolites from the kidneys. While beneficial, it is <strong>not as effective as Amifostine</strong> for directly protecting against nephrotoxicity.</li>
</ul>
<li><strong>Furosemide:</strong></li>
<ul>
<li><strong>Use:</strong> A loop diuretic sometimes used to manage fluid overload but has <strong>no specific protective effects</strong> against cisplatin-induced nephrotoxicity. Additionally, it may exacerbate electrolyte imbalances, increasing toxicity risks.</li>
</ul>
</ul>
<p><strong>Important Clinical Points from the Content:</strong></p>
<p><strong>Complications of Chemotherapy Drugs:</strong></p>
<ul>
<li><strong>SIADH (Syndrome of Inappropriate Antidiuretic Hormone):</strong>
<ul>
<li><strong>Drug Responsible:</strong> <strong>Vincristine</strong> (causes ectopic ADH release).</li>
<li><strong>Mechanism:</strong> Leads to hyponatremia due to water retention.</li>
</ul>
</li>
<li><strong>Cisplatin Complications:</strong>
<ul>
<li><strong>Ototoxicity:</strong> Damages cochlear hair cells.</li>
<li><strong>Maximum Nausea and Vomiting:</strong> Strong stimulation of the CTZ.</li>
<li><strong>Nephrotoxicity:</strong> Damages renal tubular cells via oxidative stress and toxic metabolites.</li>
</ul>
</li>
</ul>
<p><strong>Management of Cisplatin Side Effects: </strong></p>
<ul>
<li><strong>Nausea and Vomiting:</strong>
<ul>
<li><strong>Ondansetron:</strong> A 5-HT3 receptor antagonist.</li>
</ul>
</li>
<li><strong>Nephrotoxicity:</strong>
<ul>
<li><strong>Amifostine:</strong> Cytoprotective agent.</li>
<li><strong>NaCl (Chloride diuresis):</strong> Reduces cisplatin binding to renal tissues.</li>
<li><strong>Mannitol:</strong> Promotes diuresis, flushing out toxic metabolites.</li>
</ul>
</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 12</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A 60-year-old male presents to the emergency department with symptomatic bradycardia and hypotension. His ECG shows a heart rate of 40 bpm. Which of the following drugs is the first-line treatment for bradycardia at a dose above 0.5 mg?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Edrophonium</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Atropine</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Epinephrine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Propranolol</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Atropine is a <strong>parasympatholytic (anticholinergic)</strong> drug that blocks muscarinic receptors in the heart. It inhibits vagal stimulation, leading to an <strong>increase in heart rate and AV conduction</strong>. It is the <strong>drug of choice (DOC)</strong> for symptomatic bradycardia when given at doses above 0.5 mg. Lower doses (&lt;0.5 mg) may paradoxically cause bradycardia due to partial vagal blockade.</p>
<p><strong>Distractors: &nbsp;</strong></p>
<ul>
<li><strong>Edrophonium:</strong> A <strong>parasympathomimetic</strong> that increases acetylcholine by inhibiting acetylcholinesterase, leading to a <strong>decrease in heart rate and AV conduction</strong>. While it can terminate supraventricular tachycardia (SVT), it is not used for bradycardia.</li>
<li><strong>Epinephrine:</strong> A <strong>sympathomimetic</strong> that stimulates beta-1 receptors, increasing heart rate, AV conduction, and myocardial contractility. It is preferred in <strong>pediatric bradycardia</strong> and <strong>cardiac arrest</strong> but is <strong>not first-line for adult bradycardia</strong>, where atropine is favoured.</li>
<li><strong>Propranolol:</strong> A <strong>sympatholytic (beta-blocker)</strong> that decreases heart rate, AV conduction, and myocardial contractility. It is contraindicated in bradycardia as it can exacerbate the condition.</li>
</ul>
<p><strong>Table: </strong>Effects of Autonomic Drugs on the Heart</p>
<table style="border-collapse: collapse; width: 100%;" border="1">
<tbody>
<tr>
<td style="width: 32.7338%;">
<p><strong>System</strong></p>
</td>
<td style="width: 18.3453%;">
<p><strong>Effect on Heart</strong></p>
</td>
<td style="width: 21.0432%;">
<p><strong>Examples</strong></p>
</td>
<td style="width: 27.8777%;">
<p><strong>Clinical Uses</strong></p>
</td>
</tr>
<tr>
<td style="width: 32.7338%;">
<p><strong>Parasympathomimetic</strong></p>
</td>
<td style="width: 18.3453%;">
<p>&darr; HR and AV conduction</p>
</td>
<td style="width: 21.0432%;">
<p><strong>Edrophonium</strong></p>
</td>
<td style="width: 27.8777%;">
<p>Used in <strong>PSVT/SVT</strong> to slow conduction through the AV node.</p>
</td>
</tr>
<tr>
<td style="width: 32.7338%;">
<p><strong>Parasympatholytic</strong></p>
</td>
<td style="width: 18.3453%;">
<p>&uarr; HR and AV conduction</p>
</td>
<td style="width: 21.0432%;">
<p><strong>Atropine</strong></p>
</td>
<td style="width: 27.8777%;">
<p><strong>DOC for bradycardia</strong> (&gt;0.5 mg) and <strong>AV block (digoxin toxicity)</strong>.</p>
</td>
</tr>
<tr>
<td style="width: 32.7338%;">
<p><strong>Sympathomimetic</strong></p>
</td>
<td style="width: 18.3453%;">
<p>&uarr; HR, AV conduction and contractions</p>
</td>
<td style="width: 21.0432%;">
<p><strong>Epinephrine</strong></p>
</td>
<td style="width: 27.8777%;">
<p>Used in <strong>pediatric bradycardia</strong> and <strong>cardiac arrest</strong>.</p>
</td>
</tr>
<tr>
<td style="width: 32.7338%;">
<p><strong>Sympatholytic</strong></p>
</td>
<td style="width: 18.3453%;">
<p>&darr; HR, AV conduction and contractions</p>
</td>
<td style="width: 21.0432%;">
<p><strong>Beta-blockers (e.g., Propranolol)</strong></p>
</td>
<td style="width: 27.8777%;">
<p>DOC for <strong>rate control in A. fibrillation/flutter</strong>, <strong>HOCM</strong>, and <strong>aortic dissection</strong>.</p>
</td>
</tr>
</tbody>
</table>
<p><strong>Clinical Pearls: </strong></p>
<ul>
<li><strong>Bradycardia DOC:</strong> Atropine (first-line); epinephrine (children or refractory cases).</li>
<li><strong>PSVT/SVT Termination:</strong> Edrophonium slows AV conduction by increasing vagal tone.</li>
<li><strong>Atrial Fibrillation/Flutter Rate Control:</strong> Beta-blockers decrease heart rate by blocking beta-1 adrenergic receptors.</li>
<li><strong>Caution with Atropine:</strong> Low doses (&lt;0.5 mg) can paradoxically worsen bradycardia.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 13</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following patients is contraindicated for metformin therapy due to an increased risk of lactic acidosis?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>A 30-year-old with metabolic syndrome</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>A 45-year-old smoker with type 2 diabetes mellitus</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>A 60-year-old chronic alcoholic with liver cirrhosis</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>A 50-year-old with polycystic ovary syndrome (PCOS)</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Metformin, a <strong>biguanide</strong>, primarily acts by stimulating <strong>AMP-activated protein kinase (AMPK)</strong>, leading to a reduction in hepatic glucose production and increased peripheral insulin sensitivity. While it is the <strong>drug of choice (DOC)</strong> for type 2 diabetes mellitus (T2DM), metabolic syndrome, and PCOS, it carries a risk of <strong>lactic acidosis</strong>, especially in patients with the following contraindications:</li>
<li><strong>Renal or hepatic failure</strong>: Both impair drug clearance and lactate metabolism, increasing lactic acidosis risk.</li>
<li><strong>Chronic alcoholism</strong>: Leads to liver dysfunction and depletion of gluconeogenic substrates, further exacerbating lactic acid levels.</li>
<li><strong>Conditions with hypoxia</strong>: Such as congestive heart failure (CHF) or severe respiratory distress, which impair lactate metabolism.</li>
<li>In this case, a 60-year-old chronic alcoholic with liver cirrhosis has significant hepatic dysfunction, making metformin use contraindicated due to the heightened risk of lactic acidosis.</li>
</ul>
<p><strong>Distractors: &nbsp;</strong></p>
<ul>
<li><strong>A 30-year-old with metabolic syndrome:</strong> Metformin is the <strong>DOC for metabolic syndrome</strong> because it improves insulin sensitivity, reduces hepatic gluconeogenesis, and aids in weight loss. It is not contraindicated.</li>
<li><strong>A 45-year-old smoker with type 2 diabetes mellitus:</strong> Smoking is <strong>not a contraindication</strong> for metformin use. However, smoking may exacerbate vascular complications of diabetes, requiring additional counseling.</li>
<li><strong>A 50-year-old with polycystic ovary syndrome (PCOS):</strong> Metformin is widely used in PCOS as it reduces insulin resistance, restores ovulatory cycles, and aids weight loss. It is safe in this scenario.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 14</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following loop diuretics is the most potent in its action?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Furosemide</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Torsemide</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Bumetanide</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Ethacrynic acid</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Loop diuretics act by <strong>blocking the Na+/K+/2Cl- symporter in the thick ascending limb of the loop of Henle</strong>, thereby inhibiting sodium, potassium, and chloride reabsorption. This action leads to a significant diuretic effect and promotes water excretion, making loop diuretics highly effective even in cases of <strong>low GFR (&lt;40 mL/min)</strong>.</li>
</ul>
<ul>
<li><strong>Bumetanide:</strong></li>
<ul>
<li>Recognized as the <strong>most potent</strong> loop diuretic, meaning it achieves the greatest diuretic effect at lower doses compared to others.</li>
<li>Despite its potency, its duration of action is shorter than some other loop diuretics.</li>
</ul>
</ul>
<p><strong>Distractors:</strong></p>
<ul>
<li><strong>Furosemide:</strong></li>
<ul>
<li>It is the <strong>DOC for cardiogenic pulmonary edema</strong> due to its rapid onset of action and vasodilatory effect mediated via prostaglandins. However, it is less potent than bumetanide.</li>
<li>Its efficacy is reduced when combined with NSAIDs due to the inhibition of prostaglandin-mediated vasodilation.</li>
</ul>
<li><strong>Torsemide:</strong></li>
<ul>
<li>Known for being the <strong>longest-acting</strong> loop diuretic, offering prolonged diuretic effects but with less potency compared to bumetanide.</li>
<li>Often preferred in chronic conditions requiring sustained diuresis.</li>
</ul>
<li><strong>Ethacrynic acid:</strong></li>
<ul>
<li>The <strong>most ototoxic</strong> loop diuretic, with limited use due to its higher risk of hearing damage.</li>
<li>It is a non-sulfonamide alternative, used in patients allergic to sulfa drugs.</li>
</ul>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 15</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following is not an appropriate indication for vancomycin therapy?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Methicillin-resistant Staphylococcus aureus (MRSA) infection</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Enterococcus faecium endocarditis in combination with gentamicin</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Pseudomembranous enterocolitis due to Clostridium difficile</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Community-acquired pneumonia caused by Streptococcus pneumoniae</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Vancomycin</strong> is a glycopeptide antibiotic primarily used to treat serious Gram-positive bacterial infections, especially in cases resistant to beta-lactams. It is ineffective against most Gram-negative bacteria due to its inability to penetrate the outer membrane.</li>
<li>While vancomycin is highly effective against MRSA, <em>Enterococcus faecium</em> (with gentamicin), and <em>Clostridium difficile</em>, <strong>community-acquired pneumonia caused by <em>Streptococcus pneumoniae</em></strong> is typically treated with beta-lactams (like penicillin or ceftriaxone) or macrolides, unless resistance is suspected.</li>
</ul>
<p><strong>Key Points:</strong></p>
<ul>
<li><strong>MRSA infections:</strong> Vancomycin is the <strong>DOC for MRSA</strong>, given IV for systemic infections.</li>
<li><strong>Enterococcus faecium endocarditis:</strong> Requires synergy with gentamicin for effective treatment.</li>
<li><strong>Pseudomembranous enterocolitis:</strong> Though oral vancomycin is effective, <strong>fidaxomicin</strong> is now the latest <strong>DOC</strong> due to its superior efficacy and lower recurrence rates.</li>
</ul>
<p><strong>Distractors:</strong></p>
<ul>
<li><strong>Methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) infection:</strong> Vancomycin is the <strong>DOC</strong> for serious MRSA infections, including bloodstream infections and pneumonia.</li>
<li><strong><em>Enterococcus faecium</em></strong><strong> endocarditis in combination with gentamicin:</strong> The combination exploits vancomycin's bactericidal action and gentamicin's synergy, making it standard therapy for resistant <em>Enterococcus</em> species.</li>
<li><strong>Pseudomembranous enterocolitis due to <em>Clostridium difficile</em>:</strong> Vancomycin (oral) is effective for severe cases of <em>C. difficile</em> infections. However, <strong>oral fidaxomicin</strong> is now preferred due to its lower recurrence rates.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 16</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following is a unique property of cocaine compared to other local anesthetics?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Blocks voltage-gated sodium channels without affecting neurotransmitter uptake.</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Causes potent vasodilation at the site of application.</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Blocks norepinephrine reuptake, leading to sympathetic stimulation.</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Is metabolized exclusively by hepatic enzymes.</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Cocaine</strong> is a local anesthetic with a unique property among its class: it inhibits the <strong>reuptake of norepinephrine, dopamine, and serotonin</strong> at synaptic clefts.</li>
<li>This results in increased levels of norepinephrine in the synapse, causing <strong>sympathetic stimulation</strong> manifested as <strong>vasoconstriction, tachycardia, and hypertension</strong>.</li>
<li>Its dual mechanism includes:</li>
<ul>
<li><strong>Blocking voltage-gated sodium channels</strong> to induce local anesthesia.</li>
<li><strong>Inhibiting norepinephrine reuptake</strong>, leading to systemic adrenergic effects.</li>
</ul>
</ul>
<p><strong>Key Points:</strong></p>
<ul>
<li>Unlike most local anesthetics, which cause <strong>vasodilation</strong>, cocaine causes <strong>vasoconstriction</strong>, making it useful in surgeries requiring hemostasis (e.g., nasal surgeries).</li>
<li>Cocaine is metabolized by <strong>plasma esterases</strong>, contributing to its short duration of action.</li>
</ul>
<p><strong>Distractors:</strong></p>
<ul>
<li><strong>Blocks voltage-gated sodium channels without affecting neurotransmitter uptake:</strong> Incorrect: While cocaine blocks voltage-gated sodium channels for its anesthetic effect, it uniquely inhibits neurotransmitter reuptake, unlike most other local anesthetics.</li>
<li><strong>Causes potent vasodilation at the site of application:</strong> Incorrect: Cocaine causes <strong>vasoconstriction</strong>, a distinguishing feature among local anesthetics. This property is due to its sympathetic stimulatory effects from norepinephrine reuptake inhibition.</li>
<li><strong>Is metabolized exclusively by hepatic enzymes:</strong> Incorrect: Cocaine is primarily metabolized by <strong>plasma esterases</strong>, with hepatic metabolism playing a secondary role. &nbsp;</li>
</ul>
<p><strong>Key Points from the Content (Integrated into Rationale):</strong></p>
<p><strong>Drugs Metabolized by Plasma Esterases:</strong></p>
<ul>
<li>Mnemonic: <strong>"Plasma Esterase Can Readily Metabolise Short Acting drugs."</strong></li>
<ul>
<li><strong>Procaine</strong>, <strong>Cocaine</strong>, <strong>Esmolol</strong>, <strong>Clevidipine</strong>, <strong>Remifentanil</strong>, <strong>Remimazolam</strong>, <strong>Mivacurium</strong>, <strong>Succinylcholine</strong>, <strong>Acetylcholine</strong>.</li>
</ul>
<li>Cocaine&rsquo;s metabolism by plasma esterases ensures a short duration of action.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 17</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following is the most appropriate use for acetazolamide (a carbonic anhydrase inhibitor)?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Acute pulmonary edema</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Chronic hypertension</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Acute mountain sickness</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Diuretic therapy for heart failure</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Acetazolamide</strong> is a <strong>carbonic anhydrase inhibitor</strong>, primarily acting in the <strong>proximal convoluted tubule (PCT)</strong> of the kidney. It works by inhibiting the enzyme carbonic anhydrase, which is involved in the reabsorption of bicarbonate, leading to <strong>increased excretion of bicarbonate, sodium, and water</strong>, resulting in diuresis.</li>
<li><strong>Acetazolamide</strong> is the <strong>drug of choice (DOC)</strong> for <strong>acute mountain sickness (AMS)</strong>, as it helps by <strong>increasing ventilation</strong> through metabolic acidosis, which compensates for the reduced oxygen levels at high altitudes. It helps prevent or alleviate symptoms of AMS such as headaches, nausea, and dizziness.</li>
</ul>
<p><strong>Key Points: </strong></p>
<ul>
<li><strong>Acetazolamide</strong> has a unique role in <strong>mountain sickness</strong> management due to its ability to stimulate breathing through inducing mild metabolic acidosis, improving oxygenation in high altitudes.</li>
<li>It is also used in <strong>familial hypokalemic periodic paralysis</strong>, a condition where the body's ability to handle potassium is impaired, and acetazolamide can help manage the condition by <strong>correcting the electrolyte imbalance</strong>.</li>
</ul>
<p><strong>Distractors: </strong></p>
<ul>
<li><strong>Acute pulmonary edema:</strong> Incorrect: While diuretics such as <strong>furosemide</strong> (a loop diuretic) are the mainstay of therapy in acute pulmonary edema, acetazolamide is <strong>not suitable</strong> as it is not a potent enough diuretic for this indication and lacks immediate effects on fluid volume reduction.</li>
<li><strong>Chronic hypertension:</strong> Incorrect: While diuretics like <strong>thiazides</strong> are commonly used for managing hypertension, acetazolamide is <strong>not typically used</strong> for long-term blood pressure control as its diuretic effect is modest and transient. &nbsp;</li>
<li><strong>Diuretic therapy for heart failure:</strong> Incorrect: <strong>Loop diuretics</strong> (like <strong>furosemide</strong>) are the preferred diuretics for managing <strong>heart failure</strong> due to their potent effects on fluid retention. Acetazolamide is not effective for heart failure management due to its limited diuretic potency and sodium retention. &nbsp;</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 18</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following anti-tuberculosis drugs has the highest risk of hepatotoxicity?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Isoniazid</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Rifampicin</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Pyrazinamide</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Ethambutol</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Pyrazinamide</strong> is considered to have the <strong>highest risk of hepatotoxicity</strong> among the first-line anti-tuberculosis (TB) drugs. It can lead to <strong>drug-induced liver injury</strong> and <strong>hepatitis</strong>, particularly when used in combination with other TB drugs.</li>
<li>The hepatotoxicity risk with <strong>Pyrazinamide</strong> is dose-dependent, and its potential to cause liver injury is higher than that of <strong>Isoniazid</strong> or <strong>Rifampicin</strong>.</li>
<li><strong>Pyrazinamide</strong> undergoes <strong>metabolic activation</strong> in the liver to form its active metabolite, which can damage liver cells and result in elevated liver enzymes, jaundice, and in severe cases, <strong>liver failure</strong>. <strong>Pyrazinamide</strong> should be used cautiously in patients with pre-existing liver disease or those at higher risk of liver injury. Regular <strong>liver function tests (LFTs)</strong> are recommended during treatment with <strong>Pyrazinamide</strong> to monitor for hepatotoxicity.</li>
</ul>
<p><strong>Distractors:</strong></p>
<ul>
<li><strong>Isoniazid:</strong></li>
<ul>
<li>Incorrect: While <strong>Isoniazid</strong> is associated with hepatotoxicity, <strong>Pyrazinamide</strong> is considered <strong>more hepatotoxic</strong> than Isoniazid. Both drugs have a <strong>dose-dependent</strong> hepatotoxic risk, but Pyrazinamide poses a greater risk when used as part of combination therapy.</li>
<li>Isoniazid-induced hepatotoxicity can occur in the form of <strong>hepatitis</strong>, especially in patients over 35 years, those with pre-existing liver disease, or those who consume alcohol.</li>
</ul>
<li><strong>Rifampicin: </strong></li>
<ul>
<li>Incorrect: <strong>Rifampicin</strong> also carries a risk of <strong>hepatotoxicity</strong>, but its hepatotoxic potential is lower compared to <strong>Pyrazinamide</strong>. Rifampicin can cause <strong>hepatitis</strong> and elevate liver enzymes, but the incidence of significant liver injury is <strong>lower</strong> compared to Pyrazinamide and Isoniazid.</li>
</ul>
<li><strong>Ethambutol:</strong></li>
<ul>
<li>Incorrect: <strong>Ethambutol</strong> is generally not associated with <strong>hepatotoxicity</strong>. Its primary adverse effect is <strong>optic neuritis</strong>, which can cause <strong>vision disturbances</strong>. It is not considered a significant cause of liver injury, unlike the other drugs in the TB regimen.</li>
</ul>
</ul>
<p><strong>Order of Hepatotoxicity Risk in Anti-Tuberculosis Drugs: </strong></p>
<ul>
<li><strong>Pyrazinamide &gt; Isoniazid &gt; Rifampicin</strong></li>
<ul>
<li><strong>Pyrazinamide</strong> has the <strong>highest hepatotoxicity risk</strong>, followed by <strong>Isoniazid</strong>, and then <strong>Rifampicin</strong>.</li>
</ul>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 19</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following is a delayed side effect commonly associated with Carbamazepine?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Eosinophilia</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Aplastic anemia</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Stevens-Johnson syndrome</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hyponatremia</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Hyponatremia</strong> is a <strong>delayed side effect</strong> of <strong>Carbamazepine</strong>, most commonly seen in the elderly population. This condition occurs because <strong>Carbamazepine</strong> promotes <strong>SIADH (Syndrome of Inappropriate Antidiuretic Hormone)</strong> secretion, which leads to water retention and dilution of sodium levels in the blood.</li>
<li>The onset of <strong>hyponatremia</strong> is often <strong>gradual</strong>, and it may be overlooked until it becomes clinically significant. It is one of the most common electrolyte disturbances seen with <strong>Carbamazepine</strong> therapy, particularly in older adults.</li>
<li><strong>Carbamazepine-induced hyponatremia</strong> typically manifests with symptoms such as <strong>confusion</strong>, <strong>lethargy</strong>, and <strong>seizures</strong>, especially when the sodium levels fall significantly.</li>
</ul>
<ul>
<li><strong>Elderly individuals</strong> are particularly at risk for developing <strong>hyponatremia</strong> while on <strong>Carbamazepine</strong> therapy, so <strong>regular monitoring of sodium levels</strong> is recommended.</li>
</ul>
<p><strong>Distractors: </strong></p>
<ul>
<li><strong>Eosinophilia:</strong> Incorrect: <strong>Eosinophilia</strong> is a known side effect of <strong>Carbamazepine</strong>, but it is <strong>not considered a delayed side effect</strong>. Eosinophilia can occur early in therapy and is often part of a broader allergic reaction. It may be associated with <strong>rash</strong> or <strong>fever</strong> and is seen in hypersensitivity reactions.</li>
<li><strong>Aplastic anemia:</strong> Incorrect: <strong>Aplastic anemia</strong> is a rare but serious side effect of <strong>Carbamazepine</strong>, though it is not typically a <strong>delayed side effect</strong>. This condition usually develops within a few months of therapy and presents with <strong>pancytopenia</strong> (decrease in all blood cell lines). It is <strong>not commonly observed in elderly patients</strong> compared to <strong>hyponatremia</strong>.</li>
<li><strong>Stevens-Johnson syndrome:</strong></li>
<ul>
<li>Incorrect: <strong>Stevens-Johnson syndrome</strong> (SJS) is a severe, <strong>life-threatening</strong> skin reaction that can occur with <strong>Carbamazepine</strong>, but it is <strong>not considered a delayed side effect</strong>. SJS typically occurs early in treatment, within <strong>2&ndash;8 weeks</strong>, and is associated with the presence of the <strong>HLA-B1502 gene</strong>.</li>
<li>The presence of the <strong>HLA-B1502 gene</strong> in individuals, especially those of <strong>Asian descent</strong>, significantly increases the risk of developing <strong>Stevens-Johnson syndrome</strong> when treated with <strong>Carbamazepine</strong>. &nbsp;&nbsp;</li>
</ul>
</ul>
<p><strong>Monitoring Recommendations: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
<ul>
<li><strong>Regular sodium levels</strong> should be monitored, particularly in the elderly, due to the risk of <strong>hyponatremia</strong>.</li>
</ul>
<p><strong>HLA-B1502 testing</strong> should be considered before starting <strong>Carbamazepine</strong> in <strong>Asian patients</strong> to reduce the risk of <strong>Stevens-Johnson syndrome</strong>. &nbsp;&nbsp;</p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 20</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following is the drug of choice (DOC) for SVT (Supraventricular Tachycardia) in patients with COPD or asthma?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Verapamil</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Diltiazem</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Beta-blockers</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Adenosine</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Diltiazem</strong> and <strong>Verapamil</strong> are both <strong>Calcium Channel Blockers (CCBs)</strong> that can be used intravenously (IV) and orally in the treatment of <strong>SVT</strong> (Supraventricular Tachycardia). However, <strong>Diltiazem</strong> is preferred over <strong>Verapamil</strong> in patients with <strong>COPD</strong> or <strong>asthma</strong> due to its <strong>less pronounced negative inotropic</strong> and <strong>less bronchoconstrictive effects</strong> compared to <strong>Verapamil</strong>. &nbsp;</li>
<li>Both medications work by <strong>blocking calcium channels</strong>, which helps in <strong>reducing heart rate</strong> and <strong>AV nodal conduction</strong>. However, <strong>Verapamil</strong> is more likely to cause <strong>bronchoconstriction</strong>, which can worsen <strong>asthma</strong> or <strong>COPD</strong> symptoms. <strong>Diltiazem</strong>, on the other hand, is generally <strong>better tolerated</strong> in these patients, making it the <strong>DOC</strong> in such conditions.</li>
<li><strong>Diltiazem</strong> is particularly useful in <strong>SVT</strong> management in patients with underlying <strong>COPD</strong> or <strong>asthma</strong> because it <strong>does not significantly affect respiratory function</strong> and is <strong>less likely to induce bronchospasm</strong>.</li>
</ul>
<p><strong>Key Points: </strong></p>
<ul>
<li><strong>Diltiazem</strong> has a <strong>favorable safety profile</strong> in patients with <strong>COPD</strong> or <strong>asthma</strong>.</li>
<li><strong>Verapamil</strong> should be used cautiously in these patients due to its <strong>bronchoconstrictive effects</strong>.</li>
</ul>
<p><strong>Distractors:</strong></p>
<ul>
<li><strong>Verapamil:</strong> Incorrect: <strong>Verapamil</strong> is another <strong>Calcium Channel Blocker</strong> used to treat <strong>SVT</strong>, but it is <strong>not the preferred drug</strong> in patients with <strong>COPD</strong> or <strong>asthma</strong> due to its <strong>bronchoconstrictive effects</strong>. <strong>Verapamil</strong> can potentially exacerbate <strong>bronchospasm</strong>, especially in patients with a history of <strong>respiratory diseases</strong>, making it less suitable for use in this group.</li>
<li><strong>Beta-blockers:</strong> Incorrect: <strong>Beta-blockers</strong> are contraindicated in patients with <strong>asthma</strong> and <strong>COPD</strong> because they can <strong>exacerbate bronchoconstriction</strong> by blocking <strong>&beta;2 receptors</strong> in the lungs, leading to <strong>worsened respiratory symptoms</strong>. Therefore, they are <strong>not the first-line treatment</strong> for <strong>SVT</strong> in these patients.</li>
<li><strong>Adenosine:</strong> Incorrect: <strong>Adenosine</strong> is indeed used to <strong>terminate SVT</strong>, but it is not the <strong>drug of choice</strong> for <strong>long-term management</strong> in <strong>COPD</strong> or <strong>asthma</strong> patients. Adenosine is typically administered <strong>acutely</strong> in emergency settings but is not used for <strong>chronic</strong> management.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 21</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>The furosemide injection is administered to a patient for which of the following action?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>A loop diuretic to prevent excessive fluid volume</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Acts as ACE inhibitor</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Prevents gastric movement</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Is a thiazide diuretic</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Furosemide or Lasix is a loop used to treat volume overload and edema in patients. It inhibits tubular reabsorption of sodium and chloride in the proximal and distal tubules and the thick ascending loop of Henle by inhibiting the sodium-chloride cotransport system. It further results in excess excretion of water along with sodium, chloride, magnesium, and calcium. <strong>Hence, option a. is correct.</strong></li>
<li>Thiazide diuretic such as Chlorothiazide blocks sodium-chloride channel in the proximal segment of the distal convoluted tubule. <strong>Hence, option d. is incorrect.</strong></li>
<li>ACE (Angiotensin converting enzyme) inhibitor blocks an angiotensin-converting enzyme (ACE) that converts angiotensin I to angiotensin II. A decreased production of angiotensin II enhances natriuresis, lowers blood pressure, and prevents remodeling of smooth muscle and cardiac myocytes. The examples of this type of drugs are Enalapril, Captopril, etc. <strong>Hence, option b. is incorrect. </strong></li>
<li>Lasix do not have any role in preventing gastric movement, instead certain antacids decrease the gastric motility such as proton pump inhibitors, H2 receptor antagonists, etc. <strong>Hence, option c. is incorrect.</strong></li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 22</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Mother of a 3-year-old child asks the nurse about instructions following the use of a spacer. What will you tell the mother?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Mouth rinse after 30 min</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Keep breathing in spacer for 30 sec</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Deep breaths while using spacer</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Time between alternate puffs is 30 secs</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>This option advises mouth washing following a 30-minute period. To avoid any drug residue remaining in the mouth, which could potentially result in adverse effects including oral thrush or inflammation, the child should rinse their mouth right away after using a spacer. This choice is therefore wrong since it prolongs mouth washing beyond the advised duration.</li>
<li>The youngster must breathe in the spacer for five to ten breaths, or around thirty seconds, when utilizing one. This guarantees that the drug gets deep into the lungs, where it works best. By decreasing the rate at which the medicine is inhaled and lowering the amount of the drug that is deposited in the lungs, spacer devices help enhance the delivery of medication to the lungs.</li>
<li>Breathe deeply while using a spacer: Although it's typically a good idea to take deep breaths when using a spacer, this option lacks the specified 30-second time range. The absence of the specified period may cause misunderstandings or inconsistent use of the spacer device.</li>
<li>There are 30 seconds between each alternate puff. This option focuses on the intervals between drug puffs, which is significant for some inhalers but not for using a spacer. Usually used in conjunction with metered-dose inhalers (MDIs), spacers are designed to enhance medicine administration to the lungs rather than control the interval between puffs.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 23</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>During IV administration, which of the following drug causes extravasation and damage to site?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Diazepam</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Epinephrine</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Phenytoin</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Ranitidine</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Phenytoin: Phenytoin is an anticonvulsant medication used to treat seizures. Extravasation of phenytoin can cause severe tissue damage, including tissue necrosis and sloughing, due to its alkaline pH and hypertonicity. Prompt recognition and treatment of extravasation are essential to minimize tissue damage.
<ul>
<li>Diazepam: Diazepam is a benzodiazepine used to treat anxiety, seizures, and muscle spasms. While it can cause irritation at the injection site, it is not typically associated with severe extravasation or tissue damage.</li>
<li>Epinephrine: Epinephrine is a sympathomimetic medication used to treat severe allergic reactions (anaphylaxis) and cardiac arrest. While extravasation of epinephrine can cause local tissue ischemia and necrosis if not promptly treated, it is less likely to cause significant damage compared to other medications.</li>
<li>Ranitidine: Ranitidine is a histamine-2 (H2) receptor antagonist used to reduce stomach acid production and treat gastrointestinal conditions such as ulcers and gastroesophageal reflux disease (GERD). While local irritation or inflammation may occur at the injection site, ranitidine is not typically associated with significant extravasation or tissue damage.</li>
</ul>
</li>
</ul>
<p>So, of the options provided, phenytoin is the medication most likely to cause extravasation and damage to the injection site. Therefore, the correct answer is option C: Phenytoin.</p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 24</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which medication should not be administered in treatment of CSD in Lumbar puncture?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Anti-inflammatory</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Steroids</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Antibiotics</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Anesthetic</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>CSD (Cerebrospinal fluid rhinorrhea or otorrhea) refers to the leakage of cerebrospinal fluid (CSF) from the nose or ear due to a defect in the skull base. It typically requires treatment to prevent complications such as meningitis or brain abscess.</p>
<ul>
<li>In the treatment of CSD, medications such as anti-inflammatory drugs, steroids, and antibiotics may be used depending on the underlying cause and associated complications:
<ul>
<li>Anti-inflammatory drugs: These medications can help reduce inflammation and swelling, which may be beneficial in managing symptoms associated with CSD.</li>
<li>Steroids: Steroids, such as dexamethasone, can be administered to reduce inflammation and swelling, particularly in cases where there is associated cerebral edema or inflammation of the meninges.</li>
<li>Antibiotics: Antibiotics may be prescribed if there is evidence of bacterial infection or to prevent infection in cases of traumatic CSF leakage. &nbsp;</li>
</ul>
</li>
<li>However, the administration of anesthetics such as lidocaine or bupivacaine would not be appropriate in the treatment of CSD. Anesthetics are used for local or regional anesthesia to numb specific areas for procedures or surgeries. While they may be used during lumbar puncture procedures to minimize pain, they are not typically indicated for the treatment of CSF leakage.</li>
<li>Therefore, option d (Anesthetic) is the medication that should not be administered in the treatment of CSD in lumbar puncture.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 25</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A patient is on MAOI inhibitor that causes confusion, agitation and fever. These side effects are called:</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Neuroleptic malignant syndrome</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hypertensive crisis</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Fever and chills</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Nausea and vomiting</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>The two primary concerns with MAOI (Monoamine oxidase inhibitors) are a hypertensive crisis reaction and serotonin syndrome. The given clinical findings are suggestive of hypertensive crises which usually arises from the pharmacodynamic interaction of MAOIs with sympathomimetic drugs or excessive dietary tyramine intake. Therefore, patients taking MAOI antidepressants are cautioned to avoid foods that are rich in tyramine so that the hypertensive crises can be avoided. Serotonin syndrome occurs when medications that enhance serotonin availability (such as SSRIs) are taken when MAO activity is inhibited.&nbsp;<strong>Hence, option b. is correct.</strong></li>
<li>Neuroleptic malignant syndrome (NMS) is a severe disorder caused by an adverse reaction to medications with dopamine receptor-antagonist. Hence, option a. is incorrect.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 26</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A patient has been using opioids for a long time but discontinued it. The nurse anticipates the use of which drug to prevent and reduce opioid relapse?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Acamprosate</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Disulfiram</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Buprenorphine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Haloperidol</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>The chronic use of opioids can cause Opioid use disorder (OUD), which results in distress or impairment. It is characterized by an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when opioids are discontinued. The management involves replacing the problematic opioid with a safer one. These alternative agents are prescribed under medical supervision. Medication-assisted treatment (MAT) and outpatient buprenorphine office therapy (OBOT) help the patient experience reduced symptoms of drug withdrawal and cravings and little or no euphoria. <strong>Hence, option c. is correct.</strong></li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 27</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>At what time, drug reconciliation typically occurs?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>At the time of admission</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>At the time of annual checkups</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>It can occur at any stage like admission, transfer and discharge</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>At the time of discharge</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Drug reconciliation is a critical process to ensure that patients receive appropriate medications during transitions in care. This involves comparing the patient's current medication orders with the medications that the patient has been taking to avoid errors such as omissions, duplications, dosing errors, or drug interactions. &nbsp;&nbsp;&nbsp;&nbsp;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></li>
<li>At the time of admission: Drug reconciliation should definitely occur at the time of admission to ensure that the medications a patient is currently taking are accurately documented and continued if necessary. However, this is not the only time it should occur.</li>
<li>At the time of annual checkups: While medication reviews are important during annual checkups, drug reconciliation specifically is more critical during transitions in care.</li>
<li>It can occur at any stage like admission, transfer, and discharge: This is the most comprehensive and accurate option. Drug reconciliation should occur at every transition of care point: when a patient is admitted, transferred within or between facilities, and discharged. This helps to maintain an accurate and complete medication list throughout the patient's care.</li>
<li>At the time of discharge: Drug reconciliation is essential at discharge to ensure that the patient has an accurate list of medications to take home, but focusing only on discharge neglects other critical transition points.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 28</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which medication should be given to the patient with headache that occurs after the exposure of light?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Injection Ketotaolac 15 mg IV</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Injection Metoclopramide 10 mg IV</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Injection Diazepam 5 mg IV</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Injection Morphine 4 mg IV</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that is effective in treating moderate to severe pain, including migraine headaches. It helps to relieve pain and inflammation, which are common symptoms of migraines triggered by light sensitivity.</li>
<li>Injection Metoclopramide 10 mg IV: Metoclopramide is used to treat nausea and vomiting and is not typically used as a first-line treatment for migraine headaches.</li>
<li>Injection Diazepam 5 mg IV: Diazepam is a benzodiazepine used to treat anxiety, muscle spasms, and seizures, but it is not indicated for migraine headache treatment.</li>
<li>Injection Morphine 4 mg IV: Morphine is an opioid analgesic used for severe pain management, but it is not typically used as a first-line treatment for migraines and may have significant side effects.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 29</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>How to dilute the medication shown in the below given image?</strong></p>
<p><strong><img title="1.png" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/9da6ae04-d374-4aaa-a60e-9ef160bf0e41.png" alt="" width="90" height="177" /></strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>0.5 ml medicine in 1 ml saline</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>0.9 ml medicine in 1 ml saline</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>1 ml medicine in 9 ml saline</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>9 ml medicine in 1 ml saline</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Adrenaline is available in two strengths, preferred strength is 1:10 000 Adrenaline (epinephrine) = 1 mg in 10 mL.</li>
<li>The other available strength is 1:1000 Adrenaline (epinephrine) = 1 mg in 1 mL.</li>
<li>The dilution should be: first dilute to 1:10 000 by drawing up the entire contents of the ampoule (<strong>1 mL</strong>) and diluting with <strong>9 mL</strong>9% Sodium Chloride. <strong>Hence, option c. is correct.</strong></li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 30</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>What is ideal route for the administration of the medication shown in the below given image?</strong></p>
<p><strong><img title="2.jpg" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/f46ccae1-19ea-4b96-b126-638ef61009f8.jpg" alt="" width="175" height="175" /></strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Subcutaneous</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Intramuscular</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Intradermal</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Peripheral line</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>50% Dextrose Injection, USP is a sterile, nonpyrogenic, hypertonic solution of dextrose in water for intravenous injection as a fluid and nutrient replenisher. It is indicated in the treatment of insulin hypoglycemia to restore blood glucose levels.</li>
<li>The solution should be given slowly, preferably through a small-bore needle into a large vein, to minimize venous irritation.</li>
<li>Concentrated dextrose should be administered via central vein only after suitable dilution.</li>
<li>Concentrated dextrose solutions should not be administered subcutaneously or intramuscularly.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 31</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>All of the following statements regarding administration of injection vancomycin are correct, except:</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Observe for Reye&rsquo;s syndrome</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Blood C/S sample before first dose to know organism</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Frequent changing of iv line and tubing to reduce risk of phlebitis</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Slow infusion over 60 minutes</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Vancomycin does not cause Reye&rsquo;s syndrome (hepatic encephalopathy), a rare and potentially fatal pediatric illness defined as acute non-inflammatory encephalopathy with fatty liver failure.&nbsp;It is associated with aspirin consumption during viral illness or fever. <strong>Hence, option a. is correct.</strong></li>
<li>Obtaining&nbsp;bloodcultures after&nbsp;starting&nbsp;intravenous (IV) antibiotics is inherently likely to reduce the yield of positive cultures. <strong>Hence, option b. is incorrect.</strong></li>
<li>Vancomycin flushing syndrome (VFS), previously known as Redman syndrome, an infusion-related reaction associated with rapid intravenous infusion of vancomycin. Therefore, it should be infused slowly. <strong>Hence, option d. is incorrect.</strong></li>
<li>Some adverse effects of vancomycin include local phlebitis, chills, drug fever, skin rash, eosinophilia, and reversible neutropenia. Thus, the IV line should be frequently changed. <strong>Hence, option c. is incorrect.</strong></li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 32</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A female in child bearing age using antipsychotic medications. The patient should know that antipsychotic medications:</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Can increase libido</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Use contraception as earlier using in amenorrhea</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Can lead to dysmenorrhea</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Can cause irreversible amenorrhea</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Antipsychotic medications can cause amenorrhea, elevating the prolactin levels. However, the woman is still ovulating, therefore, she should continue using contraceptives to avoid unintended pregnancy. Anti-psychotic induced amenorrhea is not reliable for contraception effect. <strong>Hence, option b. is correct.</strong></li>
<li>It does not cause dysmenorrhea (painful menstruation) instead causes amenorrhea.</li>
<li>It decreases libido.</li>
<li>The amenorrhea is reversible.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 33</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>All of the following are used as anti-craving agents for alcohol dependence, except?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Lorazepam</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Acamprosate</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Topiramate</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Naltrexone</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Lorazepam is a benzodiazepine primarily used for managing acute alcohol withdrawal symptoms, such as anxiety, agitation, and seizures, rather than for reducing cravings for alcohol.</li>
</ul>
<p><strong>Rationale for other options:</strong></p>
<ul>
<li>Acamprosate: This medication is used to help maintain abstinence in people with alcohol dependence by reducing cravings.</li>
<li>Topiramate: This anticonvulsant medication has been found to reduce alcohol cravings and consumption in some studies.</li>
<li>Naltrexone: This medication is used to reduce the pleasurable effects of alcohol, thereby reducing cravings and the risk of relapse.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 34</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following anti-coagulant is contraindicated during pregnancy?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Warfarin</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Heparin</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Streptokinase</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>None of the above</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Warfarin is contraindicated during pregnancy because it can cross the placenta and has teratogenic effects, leading to a range of fetal complications such as congenital abnormalities, bleeding, and even fetal death. The use of Warfarin during pregnancy, especially in the first trimester and at term, poses significant risks to the developing fetus.</li>
</ul>
<p><strong>Rationale for other options:</strong></p>
<ul>
<li>Heparin: Heparin, including low molecular weight heparin (LMWH), is safe for use during pregnancy as it does not cross the placenta and is commonly used for anticoagulation in pregnant women.</li>
<li>Streptokinase: Streptokinase is a thrombolytic agent, not a direct anticoagulant. Its use in pregnancy is generally avoided unless absolutely necessary, but it is not as specifically contraindicated as Warfarin for long-term anticoagulation.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 35</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Doctor prescribed metoclopramide drug to the patient. Which response by the nurse would be assessed?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Peristalsis movement</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Dizziness</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hyperthermia</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Altered consciousness</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Metoclopramide is a dopamine receptor antagonist and has been approved by the FDA to treat nausea and vomiting in patients with gastroesophageal reflux disease or diabetic gastroparesis by increasing gastric motility. It increases gastric contractions, relaxes the pyloric sphincter, and&nbsp;increases peristalsis of the duodenum and jejunumresulting in accelerated gastric emptying. It is also used to control nausea and vomiting in chemotherapy patients. Therefore, the nurse should look for peristaltic movement. Hence, option a. is correct.</li>
</ul>
<p>Mechanism of action: -</p>
<p><img title="13.png" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/0947cb8a-5681-49a4-bb31-45b2890c2441.png" alt="" width="400" height="225" /></p>
<p>Uses: -</p>
<ul>
<li>Used to treat severe diabetic gastroparesis.</li>
<li>Used to prevent nausea and vomiting caused by chemotherapy or surgery.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 36</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>If patient is taking MOAI, which diet should be restricted?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Tyramine</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Tryptophan</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Transferrin</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Protein</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Monoamine oxidase inhibitors (MAOIs)</strong> block the enzyme monoamine oxidase, which is responsible for breaking down tyramine in the body. MAOIs prevent the breakdown of tyramine found in the body and in certain foods, drinks, and other medications. Patients that take MAOIs and consume tyramine-containing foods or drinks will exhibit high serum tyramine level.&nbsp;A high level of tyramine can cause a sudden increase in blood pressure, called the tyramine pressor response.&nbsp;Even though it is rare, a high tyramine level can trigger a cerebral hemorrhage, which can even result in death.</li>
<li>Examples of&nbsp;high levels of tyramine in food are types of fish and types of meat, including sausage, turkey, liver, and salami.&nbsp;Also, certain fruits can contain tyramine, like overripe fruits, avocados, bananas, raisins, or figs.&nbsp;These food products should be avoided.</li>
</ul>
<h3><strong>Distractors:</strong></h3>
<ul>
<li><strong>Tryptophan: </strong> Tryptophan is a precursor to serotonin, not norepinephrine. While it can interact with other medications like SSRIs (leading to serotonin syndrome), it is not directly associated with hypertensive crisis in MAOI therapy.</li>
<li><strong>Transferrin: </strong> Transferrin is a blood protein involved in iron transport and has no relevance to dietary restrictions or MAOI interactions. &nbsp;</li>
<li><strong>Protein: </strong> General dietary protein is not a contraindication in MAOI therapy, as it does not contain significant amounts of tyramine.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 37</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A client is admitted for pulmonary embolism and is receiving heparin 1,500 units/hour IV. In case of a serious bleeding reaction, the nurse should keep which of the following drugs readily available?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Promethazine hydrochloride</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Vitamin K</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Protamine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Protamine sulfate</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>The antidote for heparin is protamine sulfate.</li>
<li><strong>Heparin</strong> is an anticoagulant that works by inactivating thrombin and preventing blood clot formation.</li>
<li>If a <strong>serious bleeding reaction</strong> occurs, <strong>protamine sulfate</strong> is the antidote for heparin overdose or excess anticoagulation.</li>
<li><strong>Protamine sulfate</strong> binds to heparin and neutralizes its anticoagulant effect, thus reversing the bleeding risk caused by heparin therapy.</li>
<li>Protamine sulfate is <strong>administered intravenously</strong> and its dosage depends on the amount of heparin the patient has received.</li>
<li>Protamine sulfate: Positively charged molecule that binds negatively charged heparin. &nbsp;</li>
</ul>
<h3><strong>Distractors:</strong></h3>
<ul>
<li><strong>Promethazine hydrochloride: </strong> Promethazine is an antihistamine and antiemetic, used to treat nausea or allergies. It has no role in reversing the effects of heparin or treating bleeding from anticoagulation.</li>
<li><strong>Vitamin K: </strong> Vitamin K is used to reverse the effects of <strong>warfarin</strong>, a vitamin K antagonist, not heparin. It is ineffective for treating heparin overdose.</li>
<li><strong>Protamine: </strong> While protamine is the correct antidote, <strong>protamine sulfate</strong> is the precise formulation used for this purpose. "Protamine" alone is not specific enough to refer to the sulfate form, which is the medication used to neutralize heparin.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 38</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A patient is admitted in the emergency room and manifests ventricular tachycardia following an acute myocardial infarction (MI). This arrhythmia is life-threatening and must be controlled immediately. Which of the following drugs would be best to quickly control the condition?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Atropine</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Digitalis</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Lidocaine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Dobutamine</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Lidocaine is the best agent for the management of ventricular tachycardia associated with acute myocardial infarction (MI).</li>
<li>Dobutamine, digitalis, quinidine, and atropine can all induce tachyarrhythmia.</li>
<li>Lidocaine does not slow conduction and has little effect on atrial function.</li>
</ul>
<p>&nbsp; &nbsp;<strong>Table:</strong> <strong>Antiarrhythmics&mdash; sodium channel blockers (class I)</strong></p>
<table style="border-collapse: collapse; width: 100%;" border="1">
<tbody>
<tr>
<td style="width: 14.7482%;" width="126">
<p>&nbsp;</p>
</td>
<td style="width: 27.3381%;" width="225">
<p><strong>Class IA</strong></p>
</td>
<td style="width: 32.7338%;" width="221">
<p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Class IB</strong></p>
</td>
<td style="width: 25.1799%;" width="130">
<p><strong>&nbsp;&nbsp;&nbsp; Class IC</strong></p>
</td>
</tr>
<tr>
<td style="width: 14.7482%;" width="126">
<p>Examples</p>
</td>
<td style="width: 27.3381%;" width="225">
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Q</strong>uinidine</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Proc</strong>ainamide</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Disopyramid</strong>e</p>
<p>&ldquo;The <strong>Q</strong>ueen <strong>Proc</strong>laims <strong>Diso</strong>&rsquo;s <strong>pyramid</strong>.&rdquo;</p>
</td>
<td style="width: 32.7338%;" width="221">
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Lid</strong>ocaine</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Mexi</strong>le<strong>T</strong>ine</p>
<p>&ldquo;<strong>I</strong>&rsquo;d <strong>B</strong>uy <strong>Lid</strong>dy&rsquo;s <strong>Mexi</strong>can <strong>T</strong>acos.&rdquo;</p>
</td>
<td style="width: 25.1799%;" width="130">
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>F</strong>lecainide</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>P</strong>ropafenone</p>
<p>&ldquo;<strong>C</strong>an I have <strong>F</strong>ries, <strong>P</strong>lease.&rdquo;</p>
</td>
</tr>
<tr>
<td style="width: 14.7482%;" width="126">
<p>Clinical Use</p>
</td>
<td style="width: 27.3381%;" width="225">
<p>Both atrial and ventricular arrhythmias, especially re-entrant and ectopic SVT and VT.</p>
</td>
<td style="width: 32.7338%;" width="221">
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute ventricular arrhythmias (especially post- MI), digitalis-induced arrhythmias.</p>
<p>I<strong>B </strong>is <strong>B</strong>est post-MI.</p>
</td>
<td style="width: 25.1799%;" width="130">
<p>SVTs, including atrial fibrillation. Only as a last resort in refractory VT.</p>
</td>
</tr>
<tr>
<td style="width: 14.7482%;" width="126">
<p>Side Effects</p>
</td>
<td style="width: 27.3381%;" width="225">
<p>Cinchonism (headache, tinnitus with quinidine), reversible SLE-like syndrome (procainamide), HF (Disopyramide),</p>
<p>thrombocytopenia, torsades de pointes due to prolonged QT interval.</p>
</td>
<td style="width: 32.7338%;" width="221">
<p>CNS stimulation/depression, cardiovascular</p>
<p>depression.</p>
</td>
<td style="width: 25.1799%;" width="130">
<p>Pro-arrhythmic, especially post-MI</p>
<p>(Contraindicated).</p>
<p>I<strong>C </strong>is <strong>C</strong>ontraindicated in structural and ischemic heart disease.</p>
</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 39</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A patient is presented with an anaphylactic reaction following a bee sting. Which of the following is the drug of choice for treating the multiple cardiovascular and pulmonary problems that, if not promptly corrected, could lead to the patient&rsquo;s death?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Atropine</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Diphenhydramine</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Epinephrine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Isoproterenol</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Epinephrine is the drug of choice to relieve the symptoms of an acute, systemic, immediate hypersensitivity reaction to an allergen (anaphylactic shock). Subcutaneous administration of a 1:1000 solution of epinephrine rapidly relieves itching and urticaria, but more importantly may save the life of the patient when laryngeal edema and bronchospasm threaten suffocation; and severe hypotension, and cardiac arrhythmias become life-endangering too. &nbsp;</li>
<li>Norepinephrine, isoproterenol and atropine are ineffective therapies.</li>
<li>Angioedema is responsive to antihistamines (e.g., diphenhydramine), but epinephrine is necessary in the event of a severe reaction.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 40</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A client is receiving theophylline intravenously. After several dosages, the client started to become restless and complains of palpitations. The nurse determines that the client is experiencing theophylline toxicity in which of the following level?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Theophylline level of 10 mcg/mL</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Theophylline level of 15 mcg/mL</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Theophylline level of 20 mcg/mL</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Theophylline level of 25 mcg/mL</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>The therapeutic concentration for theophylline, when used as a bronchodilator to treat asthma, is generally considered to be 5 &ndash; 15 mcg/mL (28 - 83 micromol/L) for adults, 5 &ndash; 10 mcg/mL (28 &ndash; 55 micromol/L) for children and neonates.</li>
<li>Therapeutic serum levels range from 10 - 20 mcg/mL. Toxic levels are considered to be higher than 20 mcg/mL; however, adverse effects may be evident within the normal therapeutic range.</li>
<li>Theophylline toxicity occurs when serum theophylline levels surpass the levels in the therapeutic range. This can occur by intentional overdose or unintentionally when metabolism and/or clearance of theophylline is altered due to certain physiological stressors.</li>
<li>Early signs of toxicity include restlessness, nervousness, tachycardia, tremors and palpitations.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 41</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A patient with Addison&rsquo;s disease comes to the emergency department with complaints of nausea, vomiting, diarrhea, and fever. What collaborative care should the nurse expect?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>IV administration of vasopressors</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>IV administration of hydrocortisone</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>IV administration of D5W with 20 mEq KCl</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Parenteral injections of adrenocorticotropic hormone (ACTH)</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Vomiting and diarrhea are early indicators of Addisonian crisis and fever indicates an infection, which is causing additional stress for the patient.</li>
<li>Treatment of a crisis requires immediate glucocorticoid replacement and IV hydrocortisone, fluids, sodium, and glucose are necessary for 24 hours.</li>
<li>Addison&rsquo;s disease is a primary insufficiency of the adrenal gland and adrenocorticotropic hormone (ACTH) is not effective, nor would vasopressors be effective with the fluid deficiency of Addison&rsquo;s disease.</li>
<li>Potassium levels are increased in Addison&rsquo;s disease and KCl would be contraindicated.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 42</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>The physician orders gentamicin (Garamycin) for a child weighing 88 lb. If the dose range is 6 &ndash; 7.5 mg/kg/d, and the child is to receive the medication tid, what is the therapeutic range for a single dose for this child?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>20 &ndash; 40 mg</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>50 &ndash; 70 mg</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>80 &ndash; 100 mg</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>110 &ndash; 130 mg</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Determine the client&rsquo;s weight in kg = weight in pounds/2.2</li>
</ul>
<p>&nbsp;&nbsp;&nbsp; = 88 lb/2.2 kg = 40 kg</p>
<ul>
<li>The dose range = 6 - 7.5 mg/kg/day</li>
<li>To determine the range, take the dose range and multiply it by the client&rsquo;s weight: Lower range = 6 mg &times; 40 kg = 240 mg/kg/day</li>
<li>Upper range: 7.5 mg &times; 40 kg = 300 mg/kg/day</li>
<li>To find a single dose, divide each of the doses by 3 because it was ordered tid (three times a day).</li>
</ul>
<p>Single dose range = 240 mg/3 = 80 mg per dose and 300 mg/3 = 100 mg per dose. Therefore, the single dose range is 80 &ndash; 100 mg.</p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 43</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A 4-year-old child is brought to an emergency department by a parent. The parent states to a nurse, &ldquo;My child&rsquo;s behavior isn&rsquo;t right. I think some of my medication is gone.&rdquo; The parent hands the illustrated medication bottle to the nurse. Which action should the nurse take first?</strong></p>
<p><strong><img title="3.png" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/a039ced3-c94c-48a4-ad85-2ddf8f759c3b.png" alt="" width="130" height="197" /></strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Ask the mother how many tablets the child may have taken.</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Check the child&rsquo;s blood glucose level.</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Administer glucagon (GlucaGen) 1 mg subcutaneously.</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Start an infusion of D5W at 40 mL/hr.</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Glipizide is a sustained released second-generation sulfonylurea hypoglycemic agent with an onset of 15 to 30 minutes, a peak of 1 to 2 hours, and a duration of up to 24 hours. The child&rsquo;s behavior and the presence of the bottle suggest the child may have ingested some of the medication. The child&rsquo;s blood glucose level should be checked first because the mother &ldquo;thinks&rdquo; that the child may have ingested the medication. Questioning the mother about the number of tablets taken may delay the child&rsquo;s treatment.</li>
<li>An oral form of glucose should be administered if the child is responsive and glucagon administered only if the child is unresponsive or too uncooperative or upset to take oral glucose.</li>
<li>Glucagon stimulates the release of liver glycogen and releases glucose into the circulation. Initiating an intravenous access for glucose administration is more time-consuming than administering glucose by the oral route or glucagon subcutaneously to a child who is still responsive.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 44</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A child takes what comes close to being a lethal dose of acetaminophen. Which of the following is the most likely pathology involved in this drug overdose?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Acute nephropathy</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>A-V conduction disturbances, heart block</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Liver failure</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Status asthmaticus</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>The primary cause of death from acetaminophen overdoses is hepatic necrosis. The drug&rsquo;s main toxic metabolite is N-acetylbenzoqinoneimine. It reacts with sulfhydryl groups that are constituents of key macromolecules and metabolic cofactors (e.g., glutathione) in the liver. If acetaminophen doses are low, glutathione conjugates the metabolite.</li>
<li>With toxic doses, however, glutathione is depleted and other &ndash;SH groups on hepatocyte proteins are attacked and irreversibly altered. Concomitant with overall hepatic damage we find, eventually, profound hypoglycemia (as the liver&rsquo;s stores of glycogen are depleted) and coagulopathies (as hepatic clotting factor synthesis stops and the patient begins bleeding spontaneously).</li>
<li>Nephropathy (a) is not a primary or important consequence of acetaminophen toxicity.</li>
<li>If A-V conduction disturbs, heart block, or other cardiac electrophysiologic anomalies (b) occur, they are secondary to hepatic dysfunction. Status asthmaticus (d) and acute seizures (e) are not likely or direct consequences of acetaminophen poisoning. &nbsp;</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 45</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A 12-year-old boy has been treated with methylphenidate for the last 3 years. His younger sister finds the bottle of pills and consumes enough to cause significant toxicity. Which of the following findings would you most likely expect?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hypertension, tachycardia, seizures</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hypotension, bronchospasm</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Drowsiness, obtunded reflexes, diarrhea</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Miosis, bradycardia, profuse salivation, sweating</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Methylphenidate, which is widely used to manage ADD&ndash;ADHD, has amphetamine-like sympathetic and CNS&ndash;stimulating effects. Indeed, amphetamine itself is used for treatment of ADD&ndash;ADHD.</li>
<li>Peripheral sympathetic (adrenergic) effects arise from the drugs&rsquo; ability to release neuronal norepinephrine. Related findings would include increased vasoconstriction (greater &alpha;1 receptor activation of vascular smooth muscle), and therefore increased blood pressure; and tachycardia (plus increased cardiac contractility and electrical impulse conduction rates, probably accompanied by tachyarrhythmias, from &beta;<sub>1</sub> activation).</li>
<li>At toxic doses, the CNS effect of the drug is likely to cause seizures. There is no mechanism by which direct effects of methylphenidate or amphetamine (whether at normal or toxic doses) would cause bronchospasm, bronchoconstriction, or even bronchodilation (because norepinephrine that is released has no ability to activate or block &beta;<sub>2</sub> receptors on airway smooth muscle). Miosis (which occurs with either muscarinic activation or &alpha; blockade) would be the opposite of what you would predict in terms of ocular effects. &nbsp;</li>
<li>In terms of autonomic effects, skeletal muscle weakness or paralysis are findings you would expect from drugs that either blocked nicotinic cholinergic receptors (e.g., tubocurarine or another similar non-depolarizing neuromuscular blocker) or stimulated them in excessive and prolonged fashion (e.g., succinylcholine).</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 46</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A patient has received excessive doses of nitroprusside, and toxic manifestations are developing. Which of the following drugs should we administer to help nitroprusside&rsquo;s metabolism proceed to the formation of a less toxic metabolite?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Epinephrine</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Sodium thiosulfate</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Thrombin</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Vitamin C</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Cyanide, whether from nitroprusside metabolism or from other sources, normally reacts with endogenous sulfur-containing compounds, mainly thiosulfate; under the influence of mitochondrial rhodanese (a trans-sulfurase), and relatively nontoxic (less toxic than CN) thiocyanate is formed and is readily excreted in the urine.</li>
<li>With excessive exposure to nitroprusside (or CN&minus; from other sources), endogenous sulfur-containing substrate stores are depleted. We manage this, then, by IV infusion of an aqueous sodium thiosulfate solution.</li>
</ul>
<p><strong>Note:</strong> To avoid or at least reduce the risks of nitroprusside-induced cyanide toxicity, some agencies add sodium thiosulfate to the nitroprusside before the drug is administered, thereby providing ample exogenous substrate for the detoxification reaction.</p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 47</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following is a potential side effect of IV furosemide (Lasix)?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Drowsiness</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Diarrhea</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Cystitis</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hearing loss</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Patients receiving large doses of loop diuretics are at risk for developing ototoxicity.</li>
</ul>
<p><strong>Special warnings and precautions for use are as follows: </strong></p>
<ul>
<li>Patients with partial obstruction of urinary outflow (e.g. prostatic hypertrophy, hydronephrosis, ureterostenosis). Urinary output must be secured.</li>
<li>Patients with hypotension or at increased risk from pronounced fall in blood pressure (patients with coronary artery stenosis or cerebral artery stenosis).</li>
<li>Patients with manifest or latent diabetes mellitus or variation of glycaemia (regular monitoring of blood glucose levels necessary).</li>
<li>Patients with gout and hyperuricemia (regular monitoring of uric acid levels in serum necessary).</li>
<li>Patients with hepatic disease or hepatorenal syndrome (renal impairment associated to severe hepatic disease).</li>
<li>Hypoproteinemia (associated to nephrotic syndrome, furosemide&acute;s effect may be reduced and its ototoxicity increased).</li>
<li>Co-administration with lithium salts (monitoring of lithium levels is required).</li>
</ul>
<p><strong>Cautious dose; titration is required:</strong></p>
<ul>
<li>Electrolyte variations (e.g. hypokalemia, hyponatremia). Potassium supplements and/or dietary measures may be needed to control or avoid hypokalemia.</li>
<li>Fluid variations, dehydration, blood volume reduction with circulatory collapse and possibility of thrombosis and embolism, particular in elderly, with excessive use.</li>
<li>Ototoxicity (if administered faster than 4 mg/min - other ototoxic compounds administered concomitantly can increase this risk.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 48</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A 67-year-old client is to be discharged from the hospital. The client is taking digoxin and furosemide daily. Which instruction is most essential for the nurse to give this client?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Take your medicine early in the day.</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Be sure to drink orange juice and eat bananas or melons every day.</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Avoid foods that are high in sodium.</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Drink plenty of milk.</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Furosemide (Lasix) is a potassium-depleting diuretic. The client who is also taking digoxin is at greater risk for digoxin toxicity when the serum potassium is low.</li>
<li>The person must replace the lost potassium by eating foods high in potassium and possibly by taking a potassium supplement.</li>
<li>The client should also be told to take the diuretic early in the day to prevent diuresing during the night and interfering with sleep.</li>
<li>However, potassium replacement is of greater importance and takes priority. The client will also probably be told to avoid high-sodium foods but that is not the highest priority. There is no need to tell the client to drink milk.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 49</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Toxic effects of long-term administration of a glucocorticoid includes:</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hepatotoxicity</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Osteoporosis</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Precocious puberty</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Lupus like syndrome</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Glucocorticoids have lot of adverse effects on long term use.</li>
<li>Glucocorticoids decrease the function of the remaining osteoblasts directly and indirectly through the inhibition of insulin-like growth factor I expression. The stimulation of bone resorption is likely responsible for the initial bone loss after glucocorticoid exposure.</li>
<li><strong>These can lead to:</strong></li>
</ul>
<ul>
<li>Cushing syndrome</li>
<li>Hyperglycemia</li>
<li>Osteoporosis</li>
<li>Delayed wound healing</li>
<li>Increased susceptibility to infections</li>
<li>Cataract</li>
<li>Glaucoma and many other adverse effects</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 50</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Most common side effects of inhaled corticosteroids:</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Atrophic rhinitis</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Oropharyngeal candidiasis</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Pneumonia</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Pituitary adrenal suppression</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Inhaled corticosteroids (ICS) are commonly prescribed for respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD). While they are effective at reducing inflammation in the airways, they are associated with some common side effects, particularly those affecting the mouth and throat.</li>
</ul>
<p><strong>Key Points:</strong></p>
<ul>
<li>Hoarseness of voice is the most common side effects of inhalation steroids followed by oropharyngeal candidiasis<strong>. Oropharyngeal candidiasis (oral thrush)</strong> is one of the most common side effects of inhaled corticosteroids. It occurs because ICS can alter the normal flora of the oral cavity, allowing for overgrowth of fungi like <em>Candida</em>.</li>
<li>To minimize the risk of oral thrush, patients are often advised to <strong>rinse their mouth after using the inhaler</strong>.</li>
</ul>
<p>Other options: &nbsp;</p>
<ul>
<li><strong>Atrophic rhinitis</strong> is not a common side effect of inhaled corticosteroids, although nasal steroids can cause similar symptoms in some cases.</li>
<li><strong>Pneumonia</strong> is a concern with systemic steroids, especially in long-term use, but it is not as common with inhaled corticosteroids unless used in high doses. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li><strong>Pituitary adrenal suppression</strong> is a concern with long-term or high-dose systemic steroids, not typically seen with the lower doses of inhaled corticosteroids used in asthma and COPD management.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 51</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>The nurse cares for a patient taking a fluticasone/salmeterol powder inhaler BID that contains a corticosteroid. The nurse knows that teaching has been effective when the patient states:</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>&ldquo;I will shake the inhaler before using it.&rdquo;</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>&ldquo;This inhaler will act quickly to treat my shortness of breath.&rdquo;</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>&ldquo;I will use a spacing-chamber to increase the dose I receive.&rdquo;</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>&ldquo;I will rinse my mouth out after taking this medication.&rdquo;</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Powder inhalers should not be shaken as this can reduce the dose. Spacers are only used with metered-dose inhalers.</li>
<li>Corticosteroids are not emergency inhalers. They are maintenance medications so their effect is not immediate.</li>
<li>Thrush or oral candidiasis is a yeast/fungal infection of the mouth that occurs with corticosteroid use. The patient should rinse out their mouth after using the fluticasone/salmeterol powder inhaler.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 52</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Withdrawal symptoms do not usually occur in case of which of the following medications?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Monoamine oxidase inhibitors</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Non-steroidal anti-inflammatory drugs</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Selective serotonin reuptake inhibitors</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Tetracyclic anti-depressants</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Monoamine Oxidase Inhibitors (MAO inhibitors)</strong> are used to treat depressive disorders, including atypical depression (presenting with psychotic, polyphagic, or phobic features). MAO inhibitors are used less often since the introduction of SSRIs because of their dangerous interaction with foods containing tyramine.</li>
<li><strong>Selective Serotonin Reuptake Inhibitors (SSRIs)</strong> are the current first-line treatment for depressive and anxiety disorders. They prevent reuptake of serotonin by the presynaptic terminal, allowing for increased availability of serotonin to the postsynaptic membrane.</li>
<li><strong>Tricyclic Antidepressants (TCAs)</strong> can be used to treat chronic pain, major depression, and anxiety disorders. Historically, TCAs have been used in children for the treatment of enuresis.</li>
<li>The above three drugs have withdrawal effect; except Non-steroidal anti-inflammatory drugs (NASIDs).</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 53</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>You are treating an elderly postmenopausal woman with osteoporosis. She recently suffered an acute osteoporotic vertebral fracture and is suffering from secondary pain. Which of the following osteoporosis treatments also has analgesic effects with respect to bone pain?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Alendronate</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Calcitonin</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Combination of calcium and vitamin D</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Estrogen</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Calcitonin directly inhibits osteoclastic bone resorption and is considered a reasonable treatment alternative for patients with established osteoporosis in whom estrogen replacement therapy is not recommended. It has the unique characteristic of producing an analgesic effect with respect to bone pain and is often prescribed for patients who have suffered an acute osteoporotic fracture.</li>
</ul>
<p><strong>Key Points: &nbsp;</strong></p>
<ul>
<li><strong>Calcitonin</strong> helps to reduce bone pain associated with osteoporotic fractures. It has <strong>analgesic properties</strong>, which can help alleviate the pain caused by acute fractures in addition to its role in inhibiting bone resorption.</li>
<li>Calcitonin is commonly administered as a nasal spray or injection in the management of osteoporosis-related pain, especially in the acute phase following fractures. &nbsp;</li>
</ul>
<p>Other options:</p>
<ul>
<li><strong>Alendronate</strong> is a bisphosphonate that is effective in increasing bone mineral density and reducing the risk of fractures but does not have direct analgesic effects for bone pain.</li>
<li><strong>Combination of calcium and vitamin D</strong> helps with bone health by supporting calcium absorption and bone mineralization but does not have direct analgesic effects for bone pain.</li>
<li><strong>Estrogen</strong> and <strong>Raloxifene</strong> (a selective estrogen receptor modulator) are used for osteoporosis prevention and treatment, particularly in postmenopausal women, but neither has specific analgesic properties for bone pain.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 54</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>An adult client is being treated for genital herpes with acyclovir tablets. Which statement indicates that she understands her therapy?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>&ldquo;It is safe now to have sexual relations.&rdquo;</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>&ldquo;I will stay home from work until the blisters disappear.&rdquo;</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>&ldquo;This medicine will cure the herpes infection.&rdquo;</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>&ldquo;If the blisters come back, I will start taking the pills immediately.&rdquo;</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Persons with recurrent genital herpes should start taking their prescription acyclovir tablets at the first sign of an infection. This shortens the outbreak and makes it less severe.</li>
<li>The client should avoid sexual relations whenever lesions are present.</li>
<li>There is no need to stay home from work with genital herpes.</li>
<li>The medicine shortens the outbreaks and makes them less severe but does not cure herpes infections.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 55</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A patient develops sinus bradycardia. Heart rate is dangerously low and an effective and safe drug needs to be given right away. Which of the following would be the best choice?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Amiodarone</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Lidocaine</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Atropine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Edrophonium</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Sinus bradycardia can be conceptually viewed as an imbalance of two opposing factors on the SA node: (a) too great an influence of the parasympathetic nervous, specifically, of ACh acting on muscarinic receptors; or (b) too little activation of &alpha;<sub>1</sub> adrenergic receptors. We can take either or both, approaches pharmacologically.</li>
<li>Of the given answer choices, we went with atropine to block excessive parasympathetic influences and heart rate should go up.</li>
<li>Amiodarone is neither effective nor indicated for sinus bradycardia. It is used as a first-line drug for cardiac arrest; is indicated for managing some serious and life-threatening ventricular arrhythmias.</li>
<li>Lidocaine is effective for a host of ventricular arrhythmias, including those associated with an MI. It will do nothing good for the bradycardia.</li>
<li>Edrophonium would be among the worse drugs you could give this to bradycardic patient. This rapidly acting ACh esterase inhibitor will cause accumulation of even more ACh at the SA node and elsewhere in the autonomic nervous system where ACh is the neurotransmitter activating smooth muscles and various exocrine glands. If the patient&rsquo;s heart doesn&rsquo;t stop in response to edrophonium, assuming we give a usual dose, it is mere luck.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 56</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which characteristics describe the anticoagulant warfarin?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Dosage monitored using activated partial thromboplastin time (aPTT)</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Vitamin K is the antidote</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>May be administered intravenously or subcutaneously</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Protamine sulfate is the antidote</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Warfarin is a vitamin K antagonist, so vitamin K is the antidote.</li>
<li>It is monitored with the international normalized ratio (INR). It is only administered orally.</li>
<li>Protamine sulfate is the antidote for unfractionated heparin (Heparin), which can be administered subcutaneously or IV and is monitored with activated partial thromboplastin time (aPTT).</li>
<li>Hirudin derivatives are given IV or subcutaneously, do not have an antidote and are also monitored with aPTT.</li>
<li>Argatroban, a synthetic direct thrombin inhibitor, is given IV and is monitored with aPTT.</li>
<li>Factor Xa inhibitor fondaparinux is given subcutaneously and does not require routine coagulation testing.</li>
<li>Rivaroxaban, another factor Xa inhibitor, is given orally.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 57</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>The choice of coagulation study for a person who is on warfarin therapy is:</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>PT</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>INR</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>APTT</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Platelet count</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>International normalized ratio (INR) is a calculation, made to standardize prothrombin time. INR is based on the ratio of the patient's prothrombin time and the normal mean prothrombin time.</li>
<li>Prothrombin time is a test to learn how fast the blood clots in patients receiving oral anticoagulant medication.</li>
<li>APTT is used to evaluate the effect of heparin.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 58</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>The nurse prepares to discharge a patient on warfarin therapy. The nurse&rsquo;s discharge teaching should include which of the instructions?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Avoid consumption of alcoholic beverages</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Increased intake of green and leafy vegetable</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Take the medication only on an empty stomach</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Take herbal remedies to manage cold symptoms</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>When a patient is on warfarin therapy, it is crucial to follow specific dietary and lifestyle instructions to prevent complications related to bleeding or clotting. Below is the explanation for the correct answer and each distractor.</li>
</ul>
<p><strong>Avoid consumption of alcoholic beverages:</strong></p>
<ul>
<li>Alcohol can interfere with the metabolism of warfarin, increasing the risk of bleeding. It can also affect liver function, which is essential for the proper metabolism of the drug.</li>
<li>Excessive alcohol consumption may cause fluctuation in INR (International Normalized Ratio), which is a measure of how long it takes for the blood to clot. These fluctuations can make warfarin either more potent or less effective, increasing the risk of either bleeding or thrombosis.</li>
</ul>
<p><strong>Increased intake of green and leafy vegetables:</strong></p>
<ul>
<li>This is <strong>incorrect</strong>. Green leafy vegetables are rich in vitamin K, which plays a key role in blood clotting. Warfarin works by inhibiting vitamin K-dependent clotting factors. Excessive intake of vitamin K can counteract the effects of warfarin, potentially making it less effective. Patients on warfarin should maintain a consistent intake of vitamin K, not necessarily increase it.</li>
</ul>
<p><strong>Take the medication only on an empty stomach:</strong></p>
<ul>
<li>This is <strong>incorrect</strong>. Warfarin can be taken with or without food, but it is important to take it at the same time every day to maintain stable levels. There are no specific instructions to take it on an empty stomach.</li>
</ul>
<p><strong>Take herbal remedies to manage cold symptoms:</strong></p>
<ul>
<li>This is <strong>incorrect</strong>. Many herbal remedies, such as garlic, ginseng, and others, can interact with warfarin, either increasing the risk of bleeding or decreasing the drug's effectiveness. Patients should avoid herbal supplements unless approved by their healthcare provide.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 59</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>In addition to analgesia, narcotic effects include:</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Euphoria, diarrhea, increased respirations</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Euphoria, miosis, nausea and vomiting</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Respiratory depression, increased blood pressure</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Dependence, seizures, muscle spasms</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>These are the effects that often occur with the administration of narcotics. Common side effects of opioid administration include sedation, dizziness, nausea, vomiting, constipation, physical dependence, tolerance, and respiratory depression.</li>
<li>Constipation (not diarrhea) noted during the administration of narcotics. The most common side effects of opioid usage are constipation (which has a very high incidence) and nausea. These 2 side effects can be difficult to manage and frequently tolerance to them does not develop; this is especially true for constipation. They may be severe enough to require opioid discontinuation and contribute to under-dosing and inadequate analgesia.</li>
<li>Decreased respirations (not increased) are noted in narcotics administration. Decreased blood pressure results from narcotic administration. Less common side effects may include delayed gastric emptying, hyperalgesia, immunologic and hormonal dysfunction, muscle rigidity, and myoclonus.</li>
<li>Narcotics do not cause the effects in choice D at all. Physical dependence and addiction are clinical concerns that may prevent proper prescribing and in turn inadequate pain management.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 60</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following groups of clients are most at risk for GI bleeding from the use of NSAIDs?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Clients with dysmenorrhea</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Clients with headaches</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Clients with arthritis</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Clients with renal failure</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Clients with arthritis are taking the drugs for prolonged periods of time and may take higher doses. Nonsteroidal anti-inflammatory drugs (NSAIDs) are a drug class FDA-approved for use as antipyretic, anti-inflammatory, and analgesic agents.</li>
<li>These effects make NSAIDs useful for the treatment of muscle pain, dysmenorrhea, arthritic conditions, pyrexia, gout, migraines, and used as opioid-sparing agents in certain acute trauma cases.</li>
<li>Choices A and B are incorrect because the use of NSAIDs with these clients is intermittent.</li>
<li>Option A: Gastric adverse effects are likely due to the inhibition of COX-1, preventing the creation of prostaglandins that protect the gastric mucosa. The damage is more likely in a patient that has a prior history of peptic ulcers. Since it is COX-1 specific, the use of COX-2 selective NSAIDs is a lower risk alternative.</li>
<li>Option B: The main mechanism of action of NSAIDs is the inhibition of the enzyme cyclooxygenase (COX). Cyclooxygenase is required to convert arachidonic acid into thromboxanes, prostaglandins, and prostacyclins. The therapeutic effects of NSAIDs are attributed to the lack of these eicosanoids. Specifically, thromboxanes play a role in platelet adhesion, prostaglandins cause vasodilation, increase the temperature set-point in the hypothalamus, and play a role in anti-nociception.</li>
<li>Option D: Renal failure is a contraindication for NSAIDs because most of the drug is excreted through the kidneys. Renal adverse effects are because COX-1 and COX-2 facilitate the production of prostaglandins that play a role in renal hemodynamics. In a patient with normal renal function, inhibition of prostaglandin synthesis does not pose a large problem; however, in a patient with renal dysfunction, these prostaglandins play a greater role and can be the source of problems when reduced via NSAIDs. Complications that can occur due to this are acute renal dysfunction, fluid and electrolyte disorders, renal papillary necrosis, and nephrotic syndrome/ interstitial nephritis.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 61</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Morphine can be used in all, except: -</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Head injury</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Asthma</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hypothyroidism</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Diabetes</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Morphine is an opioid analgesic commonly used to treat moderate to severe pain, but it has specific contraindications and precautions in certain conditions.</p>
<ul>
<li><strong>Asthma: Morphine should generally be avoided in asthma</strong> patients because it can cause <strong>respiratory depression</strong> and <strong>bronchoconstriction</strong>, both of which can worsen asthma symptoms. Opioids, including morphine, can lead to reduced respiratory drive, which can be life-threatening in individuals with asthma, especially in acute exacerbations. Additionally, morphine can increase the risk of bronchospasm in patients with respiratory conditions like asthma.
<ul>
<li><strong>Head injury: Morphine can be used cautiously in head injury patients</strong>, but it should be monitored carefully. One of the primary concerns with morphine in head injury is that it may increase intracranial pressure (ICP) due to respiratory depression, which can be dangerous in this population. However, in cases where pain management is necessary, morphine may still be used with caution, provided that the patient's neurological status is closely monitored.</li>
<li><strong>Hypothyroidism: Morphine can be used in patients with hypothyroidism</strong>, but caution is needed because individuals with hypothyroidism may be more sensitive to opioids. They may experience more pronounced side effects such as sedation, respiratory depression, and constipation. Careful dosing and monitoring are important, but morphine is not contraindicated in hypothyroidism.</li>
<li><strong>Diabetes: Morphine can be used in patients with diabetes</strong>. However, caution is required when using morphine in diabetes because it can lead to constipation, a common side effect of opioids, which can affect the management of blood sugar levels and complicate diabetic control. But, morphine is not contraindicated in diabetes.</li>
</ul>
</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 62</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>What is the drug of choice in case of a morphine overdose?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>IV Naloxone</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Methadone</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Clonidine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Oral Naltrexone</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>IV Naloxone is the drug of choice in acute morphine overdose.</li>
<li><strong>Treatment for Opioid poisoning/Overdose: </strong>
<ul>
<li>The first step is to ensure an adequate airway. Intubation and mechanical ventilation may be necessary.</li>
<li>IV Naloxone is administered at a slow rate. Signs of improvement (increased respiratory rate and pupillary dilation) should occur promptly. If there is no response to initial dosage, repeat after a few minutes.</li>
<li>Repeated administration may be required to prevent recurrence of opioid toxicity because the duration of action of naloxone is less.</li>
</ul>
</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 63</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following is used as antidote for nicotine overdose?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Amyl nitrite</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Atropine</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Naloxone</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Bupropion</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<table style="border-collapse: collapse; width: 100%;" border="1">
<tbody>
<tr>
<td style="width: 38.6691%;" width="238">
<p><strong>Poisons</strong></p>
</td>
<td style="width: 61.3309%;" width="434">
<p><strong>Antidotes</strong></p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Acids</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>&beta;-aminoproprionitrile</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Alpha adrenergics</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Phentolamine</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Amantins</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Benzyl penicillin</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Arsenic</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Dimercaprol, Unithiol</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Benzodiazepines</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Flumazenil</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Beryllium</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Aurintricarboxylic acid, Sodium salicylate</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Beta adrenergics</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Propranolol</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Beta blockers</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Glucagon, Isoprinosine</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Botulism</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Guanidine</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Carbon monoxide</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Hyperbaric oxygen, Tocopherol</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Central anticholinergics</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Physostigmine</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Chloroquine</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Diazepam</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p><strong>Nicotine</strong></p>
</td>
<td style="width: 61.3309%;" width="434">
<p><strong>Bupropion</strong></p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Cholinergic agents</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Atropine</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Copper</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Penicillamine, Trientine</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Coumarin derivatives</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Vitamin K</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Cyanide</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Amyl nitrite, Sodium nitrite, Sodium thiosulphate (Lily&rsquo;s cyanide kit)</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Cyanide, CO<sub>2</sub>, H<sub>2</sub>S</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Oxygen</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>CO</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Hyperbaric oxygen</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Digitalis</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Digoxin specific antibody fragments</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Morphine</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Nalorphine</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Ergotism</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Sodium nitroprusside</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Heparin</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Protamine sulphate</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Insulin</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Glucose</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Iron, Aluminium</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Desferrioxamine</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Isoniazid</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Pyridoxine</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Lead, Mercury</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Succimer</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Malignant hyperthermia</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Dantrolene</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Mercury</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>N-Acetylpenicillamine</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Methanol, Ethylene glycol</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Ethanol, 4-methylpyrazole</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Opiates</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Naloxone</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Organic peroxides</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Ascorbic acid</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Organophosphates</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Oximes</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Oxalates, Fluorides</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Calcium salts</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Paracetamol</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Acetyl cysteine, Methionine</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Peripheral anticholinergics</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Neostigmine</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Radioactive metals</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Pentetic acid</p>
</td>
</tr>
<tr>
<td style="width: 38.6691%;" width="238">
<p>Thallium</p>
</td>
<td style="width: 61.3309%;" width="434">
<p>Potassium hexacyanoferrate</p>
</td>
</tr>
</tbody>
</table>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 64</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A 40-year-old woman in labor presents with high blood pressure, swelling, and protein in her urine. She is started on magnesium sulfate. Which medication should be readily available at the bedside?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Calcium gluconate</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Naloxone</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Phenytoin</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Glucose</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Calcium gluconate: </strong>Calcium gluconate is the antidote for magnesium sulfate toxicity. It is essential to have on hand because magnesium toxicity can cause severe respiratory depression, which calcium gluconate can counteract effectively.</li>
</ul>
<ul>
<li><strong>Naloxone:</strong> Naloxone is a medication used to reverse the effects of opioid overdose, particularly respiratory depression. It is not effective against magnesium sulfate toxicity.</li>
<li><strong>Phenytoin:</strong> Phenytoin is an anticonvulsant used to manage seizures, but it is not the preferred medication for women with preeclampsia and does not act as an antidote to magnesium sulfate.</li>
<li><strong>Glucose</strong>: Glucose is administered to treat low blood sugar (hypoglycemia). It has no role in reversing magnesium sulfate's effects.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 65</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A patient was brought to the emergency room with complaints of headache, vomiting, and blurring of vision after he consumed a bottle of illicit liquor. His ABG shows metabolic acidosis. Which of the following is used for the treatment of his condition?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Fomepizole</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Flumazenil</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>N-acetyl cysteine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Naloxone</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>The above clinical scenario and the Arterial blood gas analysis (ABG) showing metabolic acidosis is suggestive of <strong>methanol toxicity</strong>. <strong>Fomepizole</strong> is used for the treatment of this condition.</li>
<li><strong>Methanol poisoning</strong> is caused due to ingestion of illicit liquor which contains ethanol adulterated with methanol. Methanol is metabolized to formaldehyde and formic acid by alcohol and aldehyde dehydrogenases, respectively. The metabolites of methanol are responsible for the toxic effects.</li>
<li>Clinically, patients present with <strong>headache, vomiting</strong>, abdomen pain, uneasiness, confusion, delirium, and coma. Formic acid specifically damages the retina and optic nerve and results in <strong>blurring of vision</strong> and blindness.</li>
<li>Elevated levels of formic acid and other organic acids result in <strong>metabolic acidosis</strong> on ABG.</li>
<li>Treatment of methanol poisoning includes keeping the patient in a quiet, dark room to protect the eyes from the light. <strong>Gastric lavage</strong> with <strong>sodium bicarbonate</strong> if the patient is brought within 2 hours of ingesting methanol to combat acidosis. <strong>Ethanol infusion</strong> since ethanol is preferentially metabolized by alcohol dehydrogenase over methanol and helps by reducing the rate of generation of formaldehyde and formic acid.</li>
<li><strong>Fomepizole</strong> is a specific inhibitor of alcohol dehydrogenase and the drug of choice for methanol poisoning. Folate therapy with calcium leucovorin reduces blood formate levels by enhancing its oxidation. <strong>Hemodialysis</strong> is used in <strong>severe cases</strong> of methanol toxicity.</li>
</ul>
<p><strong>Other options: </strong></p>
<ul>
<li><strong>Option B: Flumazenil</strong> is the inverse agonist of benzodiazepine receptors and is used for the treatment of <strong>benzodiazepine overdose</strong>.</li>
<li><strong>Option C: N-acetyl cysteine</strong> is used as an antidote for the treatment of <strong>paracetamol poisoning</strong>.</li>
<li><strong>Option D: Naloxone</strong> is a competitive opioid antagonist used for the treatment of <strong>opioid overdos</strong></li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 66</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following drugs is given through rectal route?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Glyceryl trinitrate</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Isosorbide dinitrate</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Diazepam</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Verapamil</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Glyceryl trinitrate</strong> (also known as nitroglycerin) is typically administered through sublingual, transdermal, or intravenous routes for the treatment of angina. It is not usually administered via the rectal route.</li>
<li><strong>Isosorbide dinitrate</strong> is generally given orally or sublingually for angina prevention and treatment. Like glyceryl trinitrate, it is not administered rectally.</li>
<li><strong>Diazepam</strong> (a benzodiazepine) can be administered via multiple routes, including orally, intravenously, and <strong>rectally</strong>. Rectal diazepam is commonly used in the management of <strong>acute seizures</strong> or in situations where intravenous access is difficult or in cases of prolonged seizures (status epilepticus). <strong>Diazepam rectal gel</strong> is often used for pediatric and adult patients who are unable to take oral medications during a seizure episode.</li>
<li><strong>Verapamil</strong> is typically administered orally or intravenously as a calcium channel blocker used to treat hypertension, angina, and certain arrhythmias. It is not given via the rectal route.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 67</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which patient outcome would indicate to the nurse that a vasodilator medication has been effective?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Pulse rate drops from 110 to 75</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Adventitious breath sounds are absent</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Increased daily urine output</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Blood pressure decreases from 154/90 to 126/72</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Vasodilators work by relaxing blood vessels, which lowers blood pressure.</li>
</ul>
<ul>
<li><strong>Option a:</strong> A vasodilator may not necessarily decrease the pulse rate; in fact, heart rate might increase as a compensatory response to lower blood pressure.</li>
<li><strong>Option b:</strong> While vasodilators can reduce the heart's workload by lowering preload and afterload, they do not directly improve lung sounds. Any changes in breath sounds would be more related to improvements in heart failure symptoms.</li>
<li><strong>Option c:</strong> Urine output does not typically increase immediately after vasodilator administration. However, over time, better blood pressure control can support kidney function and urine production.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 68</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A patient has been diagnosed with trigeminal neuralgia. Which medication should the nurse expect to be prescribed for this patient?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Ascorbic acid</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Morphine sulfate</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Allopurinol</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Carbamazepine</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Carbamazepine is an anticonvulsant and analgesic medication commonly prescribed to manage trigeminal neuralgia. It helps control the severe facial pain associated with the condition and can prevent future pain episodes, making it a first-line treatment. In some cases, it may even reduce the necessity for surgical intervention.</li>
<li><strong>Option A: Ascorbic acid: </strong>This option is not a primary treatment for trigeminal neuralgia. Ascorbic acid (vitamin C) may be used as a supplementary treatment to support overall health, particularly during times of stress, such as pain, but it does not directly address the underlying neuralgia or provide pain relief.</li>
<li><strong>Option B: Morphine sulfate</strong>: This choice is incorrect as well. Morphine sulfate is an opioid analgesic that is effective for managing severe pain but does not prevent the recurrence of trigeminal neuralgia. Moreover, the use of morphine is generally discouraged for chronic pain conditions like trigeminal neuralgia due to the risk of dependency and the potential for side effects associated with long-term opioid use.</li>
<li><strong>Option C: Allopurinol</strong>: This option is also inappropriate for this condition. Allopurinol is primarily used in the management of gout by reducing uric acid levels in the body. It has no role in the treatment of trigeminal neuralgia and would not help alleviate the pain associated with this condition.</li>
</ul>
<p>In summary, Carbamazepine (Option D) is the most appropriate medication for managing trigeminal neuralgia, effectively controlling pain and reducing the frequency of episodes. The other options do not serve as effective treatments for this specific condition and may have alternative uses or limitations.</p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 69</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A patient of rheumatoid arthritis after being started on a therapy of DMARD develops megaloblastic anaemia in a few months. Which of the following drugs can lead to this?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Folinic acid</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Methotrexate</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Certolizumab</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hydroxychloroquine</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>DMARDS&nbsp;</strong>are disease modifying agents used in the treatment of rheumatoid arthritis.</li>
<li><strong>Methotrexate</strong>is one of the&nbsp;<strong>conventional</strong></li>
<li>Methotrexate is a&nbsp;<strong>DHFR inhibitor</strong>and thus causes&nbsp;<strong>folate deficiency.</strong> Thus, one of the major side effects of methotrexate is folic acid deficiency leading to&nbsp;<strong>megaloblastic</strong>&nbsp;</li>
<li>This can be prevented by giving&nbsp;<strong>leucovorin</strong>or&nbsp;<strong>folinic acid</strong>&nbsp;which replenishes the folic acid stores and prevents development of anaemia.&nbsp;</li>
</ul>
<p><strong>Other options:</strong></p>
<ul>
<li><strong>Folinic acid&nbsp;</strong>or leucovorin is used to prevent and treat megaloblastic anaemia caused by methotrexate.&nbsp;</li>
<li><strong>Certolizumab</strong>are&nbsp;<strong>TNF-alpha inhibitors</strong>&nbsp;and are not known to cause megaloblastic anaemia.</li>
<li><strong>Hydroxychloroquine&nbsp;</strong>inhibits lymphocytes and stabilises lysosomes. It can be used as a treatment in rheumatoid arthritis. Its major side effect is&nbsp;</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 70</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>An 11-year-old girl with complaints of abnormal body movements is diagnosed to be suffering from generalised tonic clonic seizures. Which of the following is the drug of choice?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Phenytoin</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Ethosuximide</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Retigabine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Valproate</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Generalised tonic clonic seizures</strong>(GTCS) is an epileptiform condition associated with an aura, followed by jerky spasmodic contractions of the whole body. It is often seen in children and adults. The patient has no memory of the incident after recovery. The drug of choice for GTCS is&nbsp;<strong>sodium valproate.</strong></li>
<li>It acts via prolongation of inactivation of&nbsp;<strong>sodium channels</strong>in the neurons of the CNS. Thus, it controls the excess firing of neurons, thereby preventing seizures.</li>
<li>Valproate is an enzyme inhibitor and is hepatotoxic in nature.&nbsp;&nbsp;</li>
</ul>
<p>It's <strong>side effects include:</strong></p>
<ul>
<li>Nausea and vomiting</li>
<li>Alopecia</li>
<li>Obesity</li>
<li>Pancreatitis</li>
<li>Hepatotoxicity</li>
<li>Anaemia</li>
<li>Hyperammonemia</li>
<li>Tremors</li>
<li>Teratogenicity</li>
<li>Thrombocytopenia&nbsp;</li>
</ul>
<p><strong>Other options:</strong></p>
<ul>
<li><strong>Phenytoin</strong>belongs to the hydantoin group of antiepileptics. It has several side effects including gum hyperplasia and hirsutism. It is not preferred in females.</li>
<li><strong>Ethosuximide&nbsp;</strong>blocks&nbsp;<strong>T type calcium channels.</strong>It is used in absence seizures.</li>
<li>Potassium channels are opened by drugs like&nbsp;<strong>retigabine</strong>and ezogabine. These are used in partial seizures.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 71</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>In the context of gout, which drug class is known to increase serum uric acid levels by inhibiting uric acid excretion at the renal tubules?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Diuretics</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Beta-blockers</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Proton pump inhibitors</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Nonsteroidal anti-inflammatory drugs</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Diuretics, particularly thiazide and loop diuretics, are known to increase serum uric acid levels by inhibiting uric acid excretion at the renal tubules.</li>
<li>These medications enhance the reabsorption of uric acid, leading to decreased urinary excretion and elevated serum uric acid levels.</li>
</ul>
<p><strong>Other Options:</strong></p>
<ul>
<li><strong>Option B: Beta-blockers</strong> are not associated with increased serum uric acid levels. In fact, some beta-blockers, such as propranolol, may reduce serum uric acid levels.</li>
<li><strong>Option C: Proton pump inhibitors</strong> are not known to have a significant impact on serum uric acid levels.</li>
<li><strong>Option D: NSAIDs</strong> do not directly affect uric acid excretion and are not associated with an increase in serum uric acid levels.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 72</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A patient was given halothane for general anaesthesia. He developed rigidity, and hyperthermia. These symptoms are most likely due to which ion?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Na+</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Ca2+</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>K+</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Chloride</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>The symptoms of rigidity and hyperthermia that occur during halothane anesthesia are due to an increase in intracellular calcium ion (Ca<sup>2+</sup>) concentration. Therefore, the correct option is Option B (Ca<sup>2+</sup>).</li>
<li>Succinylcholine-induced rigidity is also associated with an increase in intracellular calcium ion (Ca<sup>2+</sup>) concentration.</li>
</ul>
<p><strong>Other options:</strong></p>
<ul>
<li><strong>Option A, C and D:</strong> These options are incorrect because they are not directly involved in the mechanism of Malignant hyperthermia (MH). Malignant hyperthermia is primarily caused by abnormalities in calcium regulation within the muscle cells, rather than changes in the concentrations of other ions such as Na<sup>+</sup>, K<sup>+</sup>, or Cl<sup>-</sup>.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 73</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A young boy was brought to hospital with complaints of few episodes of fast blinking and staring at something for around 20 seconds. ECG shows spike and wave pattern. Which of the following drug should be used for treatment?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Phenytoin</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Sodium valproate</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Diazepam</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Carbamazepine</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>The symptoms described in the question suggest that the patient is experiencing absence seizures:</li>
<li>It is characterized by brief episodes of altered consciousness with staring spells and often associated with a typical electroencephalographic (EEG) pattern called a "spike and wave" discharge.</li>
<li>The drug of choice for treating absence seizures is sodium valproate. Therefore, the correct option is sodium valproate.</li>
</ul>
<p><strong>Other options: &nbsp;</strong></p>
<ul>
<li><strong>Option A and D:</strong> Phenytoin and carbamazepine are more commonly used for the treatment of partial seizures and generalized tonic-clonic seizures.</li>
<li><strong>Option C:</strong> Diazepam is often used for the treatment of status epilepticus or acute seizures, but it is not effective in the long-term management of absence seizures.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 74</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A nurse is caring for a patient receiving digoxin. Which of the following symptoms should alert the nurse for possible digoxin toxicity?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hyperkalemia</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Increased hunger</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Constipation</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Visual disturbances</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Option (d) is the correct choice because visual disturbances are a well-known indicator of digoxin toxicity. Patients experiencing digoxin toxicity may report symptoms such as blurred vision, double vision (diplopia), or changes in colour perception, which are linked to the medication's effects on the visual pathways in the brain. These symptoms warrant immediate attention, as they can signify that the digoxin levels in the body are too high, potentially leading to serious complications.</li>
<li>In addition to visual disturbances, other signs of digoxin toxicity include:</li>
<li><strong>Fatigue:</strong> Patients may feel unusually tired or weak.</li>
<li><strong>Loss of appetite:</strong> A decrease in appetite or aversion to food can occur.</li>
<li><strong>Nausea and vomiting:</strong> Gastrointestinal symptoms such as nausea may manifest.</li>
<li><strong>Confusion:</strong> Changes in mental status, including confusion or disorientation, can also be present.</li>
<li><strong>Bradycardia:</strong> A slow heart rate (bradycardia) is a critical sign of digoxin toxicity and may lead to more severe cardiac complications if not addressed promptly.</li>
</ul>
<p>The other options are not typically associated with digoxin toxicity:</p>
<ul>
<li><strong>Option (a)</strong>, hyperkalemia (elevated potassium levels), is actually more of a concern when considering the interactions of digoxin with certain diuretics and other medications. While low potassium levels (hypokalemia) increase the risk of digoxin toxicity, hyperkalemia itself is not a direct symptom of toxicity. &nbsp;</li>
<li><strong>Option (b)</strong>, increased hunger, is not relevant to digoxin toxicity and is not commonly associated with the use of this medication.</li>
<li><strong>Option (c)</strong>, constipation, can occur in patients taking various medications, including some diuretics or opioids, but it is not a recognized symptom of digoxin toxicity.</li>
</ul>
<p>In conclusion, awareness of the signs and symptoms of digoxin toxicity, particularly visual disturbances, is crucial for nurses to ensure prompt intervention and management of the patient's condition. Monitoring for these symptoms helps maintain patient safety and the effectiveness of digoxin therapy.</p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 75</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A patient visits the clinic with complaints of unexplained bruising and blood-tinged urine. Which type of medication is it most important to ask if the patient is taking?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Antibiotic</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Antipruritic</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Antianemic</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Anticoagulant</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Option (d) is the correct choice because anticoagulant medications, such as warfarin, heparin, and others, are known to increase the risk of bleeding. One of the common side effects of these medications is abnormal bleeding, which can manifest in various ways, including easy bruising and hematuria (blood-tinged urine). The presence of these symptoms raises the suspicion that the patient may be experiencing side effects related to anticoagulation therapy, potentially indicating a need for dosage adjustment or further evaluation to prevent serious complications.</li>
<li>Unexplained bruising may occur due to the inhibition of clotting factors, which impairs the body's ability to form blood clots effectively. Blood-tinged urine can result from bleeding in the urinary tract, which may occur as a consequence of anticoagulant therapy. Given these potential risks, it is crucial for the nurse or healthcare provider to inquire specifically about the patient&rsquo;s use of anticoagulants.</li>
<li>In contrast, the other options do not typically relate to the symptoms presented by the patient:</li>
<li><strong>Option (a)</strong>, antibiotics, are primarily used to treat infections and are not commonly associated with bleeding or bruising unless the patient has an adverse reaction or specific condition that predisposes them to bleeding.</li>
<li><strong>Option (b)</strong>, antipruritics, are medications used to relieve itching and do not have a known association with bruising or blood in the urine.</li>
<li><strong>Option (c)</strong>, antianemics, which are used to treat anemia, may sometimes lead to gastrointestinal bleeding if they contain iron, but they are not commonly linked with easy bruising or hematuria.</li>
</ul>
<p>In summary, when a patient present with unexplained bruising and blood-tinged urine, asking about the use of anticoagulant medications is crucial for determining the underlying cause of these symptoms and for guiding appropriate management and intervention.</p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 76</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>The following ECG shows a characteristic finding of a clinical condition. Which of the following drugs acting on the cardiovascular system is contraindicated in this condition?</strong></p>
<p><strong><img title="3.jpg" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/acb46773-ecb8-4daf-81b7-03b3a66bb458.jpg" alt="" width="335" height="230" /></strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Verapamil</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Digoxin</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Metoprolol</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>All of the above</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>The given ECG shows a delta wave, characteristic of <strong>Wolff Parkinson White syndrome</strong>. In this condition, an accessory electrical pathway called 'bundle of Kent' is present in between the atria and the ventricles. This accessory electrical pathway causes atrial signals to travel faster to the ventricle bypassing the delayed conduction through the AV node.</li>
<li><strong>AV nodal blocking</strong> agents further enhance the transmission of signals through the accessory pathway and thus aggravate the arrhythmia.</li>
<li>Further, they enhance chances of <strong>re-entry</strong> by blocking the AV nodal pathway and stimulating conduction through the accessory pathway.</li>
</ul>
<p><strong>Other options: &nbsp;</strong></p>
<ul>
<li>List of AV nodal blocking agents:
<ul>
<li>Calcium channel blockers like verapamil, diltiazem</li>
<li>Beta blockers like metoprolol, propranolol, esmolol</li>
<li>Digoxin</li>
</ul>
</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 77</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Patient education is a crucial aspect of nursing care. When educating a patient taking captopril, which common adverse effect of angiotensin-converting enzyme (ACE) inhibitors should be discussed?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Persistent cough</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Increased appetite</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hypertension</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Sedation</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Option (a) is the correct choice because a persistent cough is a well-documented and common adverse effect associated with angiotensin-converting enzyme (ACE) inhibitors, including captopril. This side effect occurs in a significant number of patients and can be bothersome enough to lead some to discontinue the medication. The cough is thought to result from the accumulation of bradykinin, a substance that is normally broken down by angiotensin-converting enzyme. When the enzyme is inhibited by medications like captopril, bradykinin levels can rise, leading to irritation of the respiratory tract and a resultant cough.</li>
</ul>
<p>Conversely, the other options do not accurately represent typical adverse effects of ACE inhibitors:</p>
<ul>
<li><strong>Option (b)</strong>, increased appetite, is not a recognized side effect of captopril or other ACE inhibitors. Patients may experience changes in appetite for various reasons, but this is not specifically linked to this class of medication.</li>
<li><strong>Option (c)</strong> is incorrect because ACE inhibitors like captopril are primarily used to treat hypertension, and their goal is to lower blood pressure rather than increase it. They are effective in managing high blood pressure and can also provide benefits for heart failure and kidney protection.</li>
<li><strong>Option (d)</strong>, sedation, is also not a typical side effect of ACE inhibitors. While some medications can cause sedation, ACE inhibitors are generally well-tolerated and do not commonly affect the central nervous system in this manner.</li>
</ul>
<p>In summary, when educating patients about captopril and other ACE inhibitors, it is essential to inform them about the potential for a persistent cough as an adverse effect. This knowledge empowers patients to recognize side effects and communicate effectively with their healthcare providers, ensuring better management of their treatment.</p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 78</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>The physician has prescribed nitroglycerin (Nitro Bid) 0.4 mg to be taken sublingually (SL) immediately. Which action shows that the nurse administered this medication in a correct manner?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Placing the tablet under the patient&rsquo;s tongue and instructing them to allow it to dissolve.</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Giving the tablet to the client with 8 oz of water after checking blood pressure and heart rate.</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Providing the tablet with 4 oz of juice to help mask the bitter taste.</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Placing the tablet under the client&rsquo;s tongue and instructing them to chew slowly to enhance absorption.</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Option (a) is the correct method for administering nitroglycerin (Nitro Bid) as it was prescribed to be given sublingually (SL). Sublingual administration is specifically designed for rapid absorption, which is achieved by placing the tablet under the tongue and allowing it to dissolve completely. This technique allows the medication to be absorbed directly into the bloodstream through the mucous membranes under the tongue, which facilitates a quicker therapeutic effect. This rapid action is especially important for nitroglycerin, which is commonly used to relieve acute chest pain (angina) by dilating blood vessels and improving blood flow to the heart.</li>
</ul>
<p>The other options are incorrect for sublingual nitroglycerin administration.</p>
<ul>
<li>Option (b) suggests swallowing the tablet with water, which would mean the drug would pass through the digestive system, delaying its effect and reducing its efficacy in an acute situation.</li>
<li>Option (c) also involves swallowing the tablet with juice, which could mask the taste but would also prevent the rapid absorption needed to relieve symptoms promptly.</li>
<li>Option (d) instructs the patient to chew the tablet, which is not appropriate for sublingual medications; chewing could lead to irregular absorption and may reduce the medication&rsquo;s effectiveness in managing symptoms swiftly.</li>
</ul>
<p>Therefore, placing the tablet under the tongue and allowing it to dissolve as per option (a) is essential to achieve the intended therapeutic effect in a timely manner.</p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 79</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>The nurse is administering low molecular weight heparin, enoxaparin. Which of the following nursing interventions is incorrect when giving this medication?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Using a TB syringe</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Injecting the medication using the Z-track method</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Not rubbing the injection site after administration</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Administering the medication in the anterolateral abdominal wall</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Option (b) is the correct choice as the Z-track method is specifically utilized for intramuscular (IM) injections to prevent the medication from leaking back into the subcutaneous tissue. Enoxaparin, a low molecular weight heparin, is typically administered subcutaneously, which does not require the Z-track technique. Instead, the standard approach involves injecting the medication into the subcutaneous tissue, usually in the anterolateral abdominal wall, to ensure proper absorption and effectiveness.</li>
</ul>
<p>The other options are appropriate nursing interventions for administering enoxaparin:</p>
<ul>
<li><strong>Option (a)</strong>, using a TB syringe, is not typically recommended. A syringe with a larger volume capacity (e.g., 1 mL or 3 mL) is more commonly used for this medication.</li>
<li><strong>Option (c)</strong>, not rubbing the injection site after administration, is correct as rubbing can cause irritation and increase the risk of bruising at the injection site.</li>
<li><strong>Option (d)</strong>, administering the medication in the anterolateral abdominal wall, is an appropriate site for subcutaneous injections of enoxaparin, as this area allows for better absorption.</li>
</ul>
<p>In summary, while administering enoxaparin, the nurse should avoid using the Z-track method and adhere to the correct protocols for subcutaneous injection.</p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 80</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A patient&rsquo;s cardiac monitor displays the following readings: HR 42/min, rhythm regular, PR interval 0.16 seconds, and QRS duration 0.06 seconds. The patient is experiencing dizziness, nausea, and chest pain rated as 3 on a scale of 1 to 10, with 10 being the worst pain. What is the most appropriate drug to treat this dysrhythmia?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Lidocaine</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Adenosine</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Atropine sulfate</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Epinephrine</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Option (c) is the correct choice because atropine sulfate is effective in treating bradycardia by blocking vagal impulses to the heart, which helps to increase the heart rate. In this case, the patient is experiencing symptomatic bradycardia (heart rate of 42 beats per minute), which can lead to symptoms such as dizziness, nausea, and chest pain.</li>
</ul>
<ul>
<li><strong>Option (a)</strong>, Lidocaine, is primarily used for the management of ventricular dysrhythmias and is not indicated for bradycardia.</li>
<li><strong>Option (b)</strong>, Adenosine, is typically used to restore normal sinus rhythm in cases of supraventricular tachycardia, not bradycardia.</li>
<li><strong>Option (d)</strong>, Epinephrine, is a catecholamine used for conditions such as anaphylaxis and severe bronchospasms. While it can increase heart rate, it is not the first-line treatment for symptomatic bradycardia.</li>
</ul>
<p>In summary, the appropriate treatment for this patient experiencing symptomatic bradycardia is atropine sulfate, as it effectively increases the heart rate by inhibiting vagal tone.</p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 81</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A 40-year-old patient with newly diagnosed hypertension is prescribed an angiotensin-converting enzyme (ACE) inhibitor. Which of the following adverse effects is commonly associated with this medication class?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hyperkalemia</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hypoglycemia</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hyperlipidemia</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hyponatremia</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>ACE inhibitors can lead to an increase in serum potassium levels (hyperkalemia).</li>
<li>This occurs because ACE inhibitors interfere with the renin-angiotensin-aldosterone system, which normally stimulates aldosterone secretion in the adrenal glands.</li>
<li>Aldosterone promotes the retention of sodium and water while increasing the excretion of potassium.</li>
<li>When ACE inhibitors block the production of angiotensin II, which normally stimulates aldosterone release, <strong>potassium excretion is reduced, potentially leading to elevated levels of potassium in the blood.</strong></li>
</ul>
<p><strong>Other Options:</strong></p>
<ul>
<li><strong>Option B:</strong> ACE inhibitors are not typically associated with hypoglycemia. However, some medications used to manage diabetes (such as insulin or certain oral hypoglycemic agents) can cause hypoglycemia.</li>
<li><strong>Option C:</strong> ACE inhibitors are not commonly associated with hyperlipidemia. Blood lipid levels are more influenced by factors such as diet, genetics, and other medications.</li>
<li><strong>Option D:</strong> ACE inhibitors are not commonly associated with hyponatremia. Hyponatremia can result from various causes, including excessive fluid intake or certain medical conditions affecting sodium balance.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 82</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>What is the most appropriate nursing intervention for an elderly client using milk of magnesia (MOM) to manage constipation?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Monitor serum electrolyte levels</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Provide supplemental vitamins B and C</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Advise the client to reduce physical activity</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Suggest the use of an incontinence pad</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Monitor serum electrolyte levels</strong> &ndash; <em>Correct</em>: Milk of magnesia can cause electrolyte imbalances, such as hypermagnesemia, requiring close monitoring.</li>
</ul>
<ul>
<li><strong>Provide supplemental vitamins B and C</strong> &ndash; <em>Incorrect</em>: MOM does not cause the depletion of water-soluble vitamins like B and C.</li>
<li><strong>Advise the client to reduce physical activity</strong> &ndash; <em>Incorrect</em>: Physical activity promotes healthy bowel movements, so limiting it would worsen constipation.</li>
<li><strong>Suggest the use of an incontinence pad</strong> &ndash; <em>Incorrect</em>: MOM generally acts gently and does not lead to incontinence in most cases.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 83</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>When managing a patient with cholecystitis, which prescribed medication should the nurse question?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Morphine</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Pro-Banthine</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Atropine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Compazine</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Morphine is generally avoided in cholecystitis because it can cause spasms in the sphincter of Oddi, worsening pain and potentially complicating bile flow. Other pain management options, such as meperidine, are preferred for this condition.</li>
</ul>
<ul>
<li><strong>Option b. Pro-Banthine</strong>: Pro-Banthine (propantheline) is an anticholinergic medication that helps reduce smooth muscle spasms and pain in cholecystitis. It is appropriate for use in this condition.</li>
</ul>
<ul>
<li><strong>Option c. Atropine</strong>: Atropine is another anticholinergic drug that can help relieve pain by relaxing smooth muscles, including those of the gallbladder. It is a suitable option for managing cholecystitis symptoms.</li>
<li><strong>Option d. Compazine</strong>: Compazine (prochlorperazine) is an antiemetic commonly used to treat nausea and vomiting, which are frequent symptoms of cholecystitis. It is appropriate for use in this context.</li>
</ul>
<p><strong>Summary:</strong> Morphine should be avoided in patients with cholecystitis because it can exacerbate symptoms by causing sphincter spasms. Anticholinergics like Pro-Banthine and atropine are effective in relieving pain, and antiemetics like Compazine address nausea and vomiting associated with the condition.</p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 84</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A 68-year-old male patient with a history of moderate persistent asthma has been prescribed theophylline as an add-on therapy. The patient presents to the clinic for a follow-up appointment. What potential adverse effect of Theophylline should be closely monitored in this patient.</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hypotension</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hyperkalemia</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Tachycardia</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hypoglycemia</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Theophylline is a medication commonly used as an add-on therapy for asthma. While it can be effective in managing asthma symptoms, it is associated with potential adverse effects, and close monitoring is necessary.</li>
<li>Theophylline can stimulate the heart and cause an increase in heart rate. In some cases, tachycardia can be significant and may require dose adjustment or discontinuation of the medication.</li>
</ul>
<p><strong>Other Options:</strong></p>
<ul>
<li><strong>Option A:</strong> Hypotension, or low blood pressure, is not a common adverse effect of theophylline. Theophylline has mild vasodilatory effects and may cause a slight decrease in blood pressure, but significant hypotension is rare.</li>
<li><strong>Option B:</strong> Hyperkalemia, or high levels of potassium in the blood, is not a common adverse effect of theophylline. Theophylline does not directly affect potassium levels.</li>
<li><strong>Option D</strong>: Hypoglycemia, or low blood sugar levels, is not a common adverse effect of theophylline. Theophylline may have a minimal effect on glucose metabolism but does not typically cause significant hypoglycemia.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 85</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Color of the shoulder of &lsquo;Oxygen Cylinder&rsquo; should be: -</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>White</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Black</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Blue</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Yellow</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Color of the shoulder of oxygen cylinder is white and the body is black.</li>
<li>International color code for oxygenation cylinder body is white. In USA, it is green.</li>
</ul>
<table style="border-collapse: collapse; width: 100%;" border="1">
<tbody>
<tr>
<td style="width: 42.2662%;" width="282">
<p><strong>Gas Cylinder</strong></p>
</td>
<td style="width: 57.7338%;" width="394">
<p><strong>Colour Code</strong></p>
</td>
</tr>
<tr>
<td style="width: 42.2662%;" width="282">
<p><strong>Oxygen</strong></p>
</td>
<td style="width: 57.7338%;" width="394">
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Body color: Black</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shoulder color: White</p>
</td>
</tr>
<tr>
<td style="width: 42.2662%;" width="282">
<p><strong>Entonox (50% N<sub>2</sub>O / 50% O<sub>2</sub>)</strong></p>
</td>
<td style="width: 57.7338%;" width="394">
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Body color: Blue</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shoulder color: White/blue quarters</p>
</td>
</tr>
<tr>
<td style="width: 42.2662%;" width="282">
<p><strong>Medical air&nbsp; (21% O<sub>2</sub> /79% N<sub>2</sub>)</strong></p>
</td>
<td style="width: 57.7338%;" width="394">
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Body color:&nbsp; Grey</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shoulder color: White/black quarters</p>
</td>
</tr>
<tr>
<td style="width: 42.2662%;" width="282">
<p><strong>Suction</strong></p>
</td>
<td style="width: 57.7338%;" width="394">
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Body color: Yellow</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shoulder color:&nbsp; Yellow</p>
</td>
</tr>
<tr>
<td style="width: 42.2662%;" width="282">
<p><strong>Nitrogen</strong></p>
</td>
<td style="width: 57.7338%;" width="394">
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Body color: Black</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shoulder color:&nbsp; Black</p>
</td>
</tr>
<tr>
<td style="width: 42.2662%;" width="282">
<p><strong>Carbon dioxide</strong></p>
</td>
<td style="width: 57.7338%;" width="394">
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Body color: Grey</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shoulder color:&nbsp; Grey</p>
</td>
</tr>
<tr>
<td style="width: 42.2662%;" width="282">
<p><strong>Helium</strong></p>
</td>
<td style="width: 57.7338%;" width="394">
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Body color: Brown</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shoulder color: Brown</p>
</td>
</tr>
<tr>
<td style="width: 42.2662%;" width="282">
<p><strong>Heliox (21%O<sub>2</sub> /79% He)</strong></p>
</td>
<td style="width: 57.7338%;" width="394">
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Body color: White</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shoulder color: Green /brown</p>
</td>
</tr>
</tbody>
</table>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 86</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>The most dangerous metabolic side effect of general anesthesia that can occur during surgery is:</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hyperglycemia</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hyperthermia</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hypoglycemia</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hypothermia</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Malignant hyperthermia is the most dangerous metabolic side effect of general anesthesia.</li>
<li>Malignant hyperthermia is a severe reaction to certain drugs used for anesthesia. This severe reaction typically includes a dangerously high body temperature, rigid muscles or spasms, a rapid heart rate, and other symptoms. Without prompt treatment, the complications caused by malignant hyperthermia can be fatal.</li>
<li>General anesthesia is more frequently associated with hyperglycemia and higher levels of catecholamines, cortisol, and glucagon than local or epidural anesthesia. Volatile anesthetic agents inhibit insulin secretion and increase hepatic glucose production.</li>
<li>Hypoglycemia is one of the most fatal complications during the perioperative period. General anesthesia or sedation can mask a hypoglycemia-altered mental status. Acute hypoglycemia might result in permanent brain injury.</li>
<li>Mild hypothermia is extremely common during anesthesia and surgery. The basic process occurs as core body heat redistributes to the skin surface through anesthetic-induced vasodilation and depression of hypothalamic thermoregulatory centers. Heat loss occurs mostly through the skin via radiation and convection.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 87</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A preoperative patient receives atropine before induction of anesthesia. The nurse caring for this patient understands that this agent is used to prevent:</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Anxiety</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Bradycardia</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Dry mouth</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hypertension</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Atropine, an anticholinergic drug, is used as an adjunct to anesthesia to counter the effects of vagal stimulation, which is caused by surgical manipulations that trigger parasympathetic reflexes, resulting in bradycardia.</li>
<li>Atropine is the first-line therapy (Class IIa) for symptomatic bradycardia in the absence of reversible causes. Treatments for bradydysrhythmias are indicated when there is a structural disease of the infra-nodal system or if the heart rate is less than 50 beats/min with unstable vital signs.</li>
<li>Atropine is not anxiolytic.</li>
<li>Atropine causes dry mouth and sometimes used to minimize bronchial secretions. While atropine can be used independently for anti-salivation effects.</li>
<li>Approximately 20% of bradydysrhythmias are due to endogenous cardiac electrical systems. The structural disease may or may not require resuscitation and should be closely monitored with medication and pacing readily available.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 88</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Prior to an eye exam, a patient is given a drug that causes mydriasis but has no effect on accommodation. What is the most likely identity of this drug?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Pilocarpine</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Mecamylamine</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Phenylephrine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Neostigmine</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Mydriasis can be caused by either a muscarinic antagonist or an alpha-1 agonist.</li>
<li>Cycloplegia (paralysis of accommodation) is caused by a muscarinic antagonist, but accommodation is unaffected by an alpha-1 agonist such as phenylephrine.</li>
<li>Remember accommodation is a parasympathetic function only.</li>
<li>Ganglionic blockade with mecamylamine would cause mydriasis and cycloplegia similar to a muscarinic blocker.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 89</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A 28-year-old woman has been treated with several autonomic drugs for about a month. Which of the following signs would distinguish between an overdose of muscarinic blocker and ganglionic blocker?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Dry mouth and constipation</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Mydriasis</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Postural hypertension</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Blurred vision</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Ganglionic blockers decrease release of both Ach and NE in the post ganglionic axons and hence will have inhibitory effect on both sympathetic and parasympathetic nervous system.</li>
<li>Muscarinic blocker antagonizes only parasympathetic nervous system.</li>
<li>Hence the common symptoms in both toxicities will be anticholinergic one like blurred vision, mydriasis, dry mouth, constipation, urine retention etc.</li>
<li>The differential symptoms in ganglionic blockers will be cause of decrease in NE, which will cause <strong>postural hypotension</strong>.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 90</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>The drug used to increase the effect of local anesthesia is:</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Epinephrine/Adrenaline</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Norepinephrine</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Atropine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Dobutamine</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Local anesthetics cause dilatation of blood vessels.</li>
<li>The addition of a vasoconstrictor such as <strong>adrenaline/epinephrine</strong> to the local anesthetic preparation diminishes local blood flow, slowing the rate of absorption and thereby prolonging the anesthetic effect.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 91</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following is the drug of choice for bradycardia in children?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>IV atropine</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>IV epinephrine</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>IV dopamine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>IV adenosine</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Epinephrine is the drug of choice for treating bradycardia in infants and children. The recommended dose is 0.01 mg/kg of a 1:10, 000 solution.</li>
<li>It can be given intravenously or via intraosseous route.</li>
<li>It can be repeated every 3-5 minutes.</li>
<li>If intravenous or intraosseous access cannot be obtained, then it can be administered via the endotracheal route at a dose of 0.1 mg/kg of a 1: 1, 000 solution.</li>
<li>If epinephrine is not effective in increasing the heart rate, then atropine can be used with a dose of 0.02 mg/kg and repeated.</li>
<li>For adults, treatment is initiated with 0.5 mg atropine IV which may be repeated at 3-5 minute intervals to a maximum dose of 3 mg. Along with atropine, transcutaneous pacing is to be done.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 92</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following drugs is not approved for resuscitation of a cardiac arrest victim?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Adrenaline</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Vasopressin</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Amiodarone</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>b and c</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Vasopressin was a part of the resuscitation protocol in the 2010 American Heart Association (AHA) cardiac arrest algorithm but it has been removed from the latest 2015 and 2020 guidelines.</li>
<li>Vasopressin causes intense peripheral vasoconstriction due to stimulation of VI receptors in the endothelium but it causes a limited increase in myocardial contractility, myocardial and cerebral oxygen consumption, and metabolic demands. Thus, it doesn't have much of a survival benefit.</li>
<li>Epinephrine and amiodarone are the two main drugs approved by the AHA for resuscitation of a cardiac arrest patient.</li>
<li>The first dose of epinephrine, 1 mg IV, is administered after the 2<sup>nd</sup> defibrillator shock is delivered and it is continued every 3-5 minutes.</li>
<li>If this is not effective, 300 mg IV bolus dose of amiodarone can be given and another dose of 150 mg is given, if necessary.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 93</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>All of the following effects are disadvantages of anticancer drugs, except:</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Low selectivity to cancer cells</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Depression of bone marrow</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Depression of angiogenesis</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Depression of immune system</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Anticancer drugs are categorized into two groups based on the stage of the cell cycle at which they act:</li>
</ul>
<ol>
<li><strong> </strong><strong>Cell cycle specific (CCS)</strong>: CCS drugs are effective when the cells are proliferating.</li>
<li><strong> </strong><strong>Cell cycle nonspecific (CCNS)</strong>: CCNS drugs are effective whether the cells are in dividing phase or are in the resting phase.</li>
</ol>
<table style="border-collapse: collapse; width: 100%;" border="1">
<tbody>
<tr>
<td style="width: 62.7698%;" colspan="2" width="424">
<p><strong>Cell Cycle Specific Inhibitors</strong></p>
</td>
<td style="width: 37.4101%;" width="240">
<p><strong>Cell Cycle Nonspecific Inhibitors</strong></p>
</td>
</tr>
<tr>
<td style="width: 34.5324%;" width="232">
<p><strong>S-Phase Inhibitors</strong></p>
</td>
<td style="width: 28.2374%;" width="192">
<p><strong>M-Phase Inhibitors</strong></p>
</td>
<td style="width: 37.4101%;" rowspan="2" width="240">
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Alkylating agents (C</strong>yclophosphamide, Ifosfamide, Mechlorethamine, Melphalan<strong>)</strong></p>
<p>&nbsp;</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Antitumor antibiotics </strong>(Mitomycin C, Anthracyclines)</p>
<p><strong>&nbsp;</strong></p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Platinum compounds </strong>(Cisplatin, Carboplatin)</p>
</td>
</tr>
<tr>
<td style="width: 34.5324%;" width="232">
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Antimetabolites</strong></p>
<p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Folic acid analogue:</strong> Methotrexate</p>
<p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pyrimidine analogue:</strong> 5FU, Capecitabine, Cytarabine</p>
<p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Purine analogue:</strong> 6 Mercaptopurine, 6 Thioguanine, Caldribine, Fludarabine</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Topoisomerase inhibitors</strong> (Irinotecan, Topotecan)</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hydroxyureas</strong></p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Histone deacetylation inhibitors</strong> (Vorinostat, Belinostat)</p>
</td>
<td style="width: 28.2374%;" width="192">
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Vinka alkaloid</strong> (Vincristine, Vinblastine)</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Estramustine</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eribulin</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Taxanes</strong> (Paclitaxel, Docetaxel, Cabazitaxel)</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ixabepilone</p>
</td>
</tr>
<tr>
<td style="width: 34.5324%;" width="232">
<p><strong>MOA:</strong></p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DHFR inhibitors (FA analogue)</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inhibit DNA synthesis by inhibiting de-novo purine and pyrimidine synthesis</p>
</td>
<td style="width: 28.2374%;" width="192">
<p><strong>MOA:</strong></p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mitotic spindle formation and breakdown inhibitors &agrave; Inhibit mitosis of cells</p>
</td>
<td style="width: 37.4101%;" width="240">
<p><strong>MOA:</strong></p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cross linking of base pairs</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal base pairing</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DNA strand breakage</p>
</td>
</tr>
</tbody>
</table>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 94</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following antibiotics is used for cancer chemotherapy?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Cytarabine</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Doxorubicin</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Gentamycin</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Etoposide</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Doxorubicin is a type of chemotherapy drug called an <strong>anthracycline</strong>. It slows down or stops the growth of cancer cells by blocking an enzyme called topoisomerase 2. Cancer cells need this enzyme to divide and grow. You might have doxorubicin in combination with other chemotherapy drugs.</li>
</ul>
<p><strong>Anthracycline: &nbsp;</strong></p>
<ul>
<li>Daunorubicin, Epirubicin, Valrubicin, Mitoxantrone</li>
</ul>
<p><strong>Mechanism of action</strong></p>
<ul>
<li>Oxygen free radicals bind to DNA causing single- and double-strand DNA breaks</li>
<li>Inhibits topoisomerase II</li>
<li>Intercalates into DNA</li>
</ul>
<p><strong>Uses</strong></p>
<ul>
<li><strong>ALL:</strong> Acute lymphoblastic leukemia</li>
<li><strong>AML:</strong> Acute myelogenous leukemia</li>
<li>Soft tissue sarcoma, ovarian cancer, nonsmall cell and small cell lung cancer, thyroid cancer, Wilms&rsquo; tumor, neuroblastoma</li>
</ul>
<p><strong>Side effects</strong></p>
<ul>
<li>Nausea, vomiting and fever</li>
<li>Red urine (not hematuria)</li>
<li>Cardiotoxicity</li>
<li>Alopecia, myelosuppression</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 95</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>General contraindications for anticancer drugs are:</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Depression of bone marrow</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Acute infections</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Severe hepatic and/or renal insufficiency</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>All of the above</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Important side effects caused by anticancer drugs:</strong></p>
<ul>
<li>Anticancer drugs mainly act by targeting the rapidly dividing cancer cells.</li>
<li>Anticancer drugs cause CTZ stimulation &agrave; causing nausea and vomiting.</li>
<li>Anticancer drugs also target the normal, rapidly dividing cells such as hair follicle, bone marrow, oral and GI mucosa, which causes some common side effects like:
<ul>
<li>Bone marrow suppression</li>
<li>Alopecia</li>
<li>Oral aphthous ulcer and GI distress</li>
</ul>
</li>
<li><strong>In addition, some other known side effects are:</strong>
<ul>
<li><strong>Pulmonary fibrosis:</strong> Bleomycin, Busulfan, Cyclophosphamide</li>
<li><strong>Cardiotoxicity</strong>: Doxorubicin/Daunorubicin, Trastuzumab</li>
<li><strong>Peripheral Neuropathy</strong><strong>, SIADH:</strong> Vinblastine/Vincristine</li>
<li><strong>Ototoxicity, Nephrotoxicity, most emetogenic</strong>: Cisplatin</li>
<li><strong>Hemorrhagic cystitis</strong>: Cyclophosphamide/Ifosfamide</li>
<li><strong>Marrow suppression:</strong> Mtx, 5FU, 6MP</li>
</ul>
</li>
</ul>
<p><img title="4.jpg" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/9d81562c-dd92-46a5-965b-862276fac61b.jpg" alt="" width="459" height="344" /></p>
<p><strong>Fig</strong>: Key chemo toxicities</p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 96</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Dextromethorphan should not be given with which drug?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>SSRIs</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>MAO inhibitors</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Atropine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Paracetamol</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Monoamine oxidase inhibitors (MAOIs) are a class of medication used to treat depression.</li>
<li>The dextromethorphan‐MAOI interaction appears to be due to a 5‐hydroxytryptamine potentiation.</li>
<li>Hypotension, hyperpyrexia and death have been reported in the patients who have been taking Monoamine oxidase inhibitors (MAOIs) with Dextromethorphan.</li>
<li>MAO inhibitors should be avoided with other antidepressants such as paroxetine fluoxetine, amitriptyline, nortriptyline, bupropion; pain medications like methadone, tramadol, and meperidine; dextromethorphan.</li>
<li>Dextromethorphan can trigger a histamine release (allergic reaction), atopic children, who are especially susceptible to allergic reactions.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 97</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which substance, when abused, can cause euphoria, drowsiness, decreased respiratory rate, and slurred speech?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Opioids</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Alcohol</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Cannabis</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Depressants</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Opioids produce these physiologic responses. Although alcohol intake can cause euphoria, drowsiness, and slurred speech, the abuser of alcohol develops tolerance and does not usually have these manifestations.</li>
<li>Effects of chronic alcohol abuse include impairment of all body systems.</li>
<li>Cannabis produces euphoria, sedation, and hallucinations.</li>
<li>Depressants may cause slurred speech and drowsiness but not euphoria or decreased respirations unless there is an overdose.&nbsp; &nbsp;</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 98</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A nurse is about to administer Naloxone hydrochloride to a client with known opioid overdose. Which of the following equipment should be readily available at bedside?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Dressing tray</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Nasogastric tube</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Resuscitative equipment</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Suction machine</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Naloxone hydrochloride (Narcan) is an opioid antagonist used for the complete or partial reversal of opioid overdose, including respiratory depression. Narcan is also used for diagnosis of suspected or known acute opioid overdose and also for blood pressure support in septic shock. Narcan is available in generic form.</li>
<li>NARCAN (naloxone) is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids, including propoxyphene, methadone and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol and cyclazocine.</li>
<li>While administering naloxone hydrochloride, resuscitation equipment, oxygen, mechanical ventilator should be readily available.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 99</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following abused drugs is related to stimulants?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Cocaine</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Amphetamine</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Caffeine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>All of the above</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Drugs can be categorized on the basis of the way in which they affect our bodies:</p>
<ul>
<li><strong>Depressants:</strong> Slow down the function of the central nervous system.</li>
<li><strong>Hallucinogens:</strong> Affect your senses and change the way you see, hear, taste, smell or feel things.</li>
<li><strong>Stimulants:</strong> Speed up the function of the central nervous system.</li>
</ul>
<p>&nbsp;</p>
<p><strong>Stimulants</strong></p>
<ul>
<li>Stimulants including cocaine, amphetamine, caffeine, and nicotine activate the CNS by increasing the concentration of dopamine.</li>
<li>Caffeine and nicotine are the two most commonly abused stimulants.</li>
<li>Stimulants speed up the messages between the brain and the body. This can cause:</li>
<li>Heart to beat faster</li>
<li>blood pressure to go up</li>
<li>Body temperature to go up &ndash; leading to heat exhaustion or even heat stroke</li>
<li>Reduced appetite</li>
<li>Agitation</li>
<li>Sleeplessness</li>
<li><strong>Examples include:</strong></li>
<li>Amphetamines (speed and ice)</li>
<li>Caffeine</li>
<li>Cocaine</li>
<li>Ecstasy (MDMA &ndash; methylenedioxymethamphetamine)</li>
<li>Nicotine (tobacco) &nbsp;</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 100</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following agents is related to hallucinogens?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Heroin</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>LSD</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Cocaine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Opium</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Hallucinogens are chemicals that alter sensory perception, mood, and thought patterns.</li>
<li>Hallucinogen use begins most commonly in adolescence and is more common in males.</li>
<li>Lysergic acid diethylamide (LSD) is the prototypical and most historically studied hallucinogen.</li>
<li>Phencyclidine (PCP) is another hallucinogen that is known to cause dissociative effects, anesthesia, and aggressive behavior.</li>
<li>Small doses can cause a feeling of floating, numbness, confusion, disorientation, or dizziness.</li>
<li>Larger doses may cause hallucinations, memory loss, distress, anxiety, increased heart rate, paranoia, panic and aggression.</li>
<li><strong>Examples include:</strong>
<ul>
<li>Cannabis</li>
<li>Ketamine</li>
<li>LSD (lysergic acid diethylamide)</li>
<li>Psilocybin (magic mushrooms)</li>
<li>PCP (phencyclidine)</li>
</ul>
</li>
</ul>
</body>
</html></li></ul></div></div>
        <div class="credits">
            <p class="rainbow-text">Credit: Code Written by BHASKAR</p>
        </div>
        </body></html>